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Abstract | Resumo  
 
Background/aims: In Portugal, there wasn’t a multicentric study on the general characteristics 
(demography, disease milestones, DMT, socioeconomic status) of Multiple Sclerosis patients.  
Methods: Patients fulfilling McDonald 2010 criteria were sequentially recruited from May to 
November 2014 in 7 centers and data was systematically collected. 
Results: 561 patients included. First symptoms occurred at 30,2±10,5 years-old (RRMS  29,2±10, 
PPMS 39,4±11,7, p<0,001); diagnosis 3,2±5,3 years later (RRMS 3,0±5,1, PPMS 4,9±2,5, 
p=0,002); 9,4±7,2 years elapsed since diagnosis (similar for those is RRMS at diagnosis and 
PPMS); current age 42,9±12,4 years-old (group RRMS at diagnosis 42,0±12,1, PPMS 52,5±11,3, 
p<0,001); current EDSS 2,5 (RRMS 2.0, PPMS 6.0); females to males 2,5:1 (RRMS similar, PPMS 
1,1:1, p<0,05); at diagnosis RRMS 90,6%, SPMS 0,9%, PPMS 8,6%; 9,5% of RRMS reached SP at 
inclusion (those older at diagnosis, in actuality, or with longer follow-up). PPMS more frequent 
in patients diagnosed at older ages (p<0,001), also slight increase in females. Along the last 
decades: new cases have showed stable proportions of gender and disease types; age at first 
symptoms and diagnosis slightly increased, time between them slightly decreased. Proportion on DMT 
(May 2014): 84,5% of all; 90,4% of currently in RRMS; 70,8% of SPMS; 36,8% of PPMS; 48% of 
progressive forms together. Type of DMT, all patients: interferons 56,5%, Glatiramer Acetate 
18,4%, Natalizumab 11,6%, Fingolimod 9,7%. Economically active 61,5% of all, unemployment 
13,5%, 74,1% of non-active are retired due to disease. Females pregnant after diagnosis 15%. 
Positive family cases in 7,8%.  
Discussion/Conclusions: 10% of the national MS population collected. Data generally consistent 
with international reports. Proportion under DMT relatively high in all disease types, but second 
line therapies underrepresented. Young patients with mild disease have an active economic life. 
Those not active are essentially retired due to disease. 
 
 
Introdução e objetivos: Não existia um estudo multicêntrico que descrevesse as características 
dos doentes com EM, da doença em si, ou do seu tratamento, em Portugal.   
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Métodos: Doentes McDonald 2010 positivos foram sequencialmente recrutados em 7 centros 
entre Maio e Novembro 2014. Aplicou-se um Caderno de Recolha de Dados incidindo na 
demografia, doença, educação e emprego (estudo PORT-MS).  
Resultados: 561 doentes incluídos. Primeiros sintomas aos 30,2±10,5 anos (RRMS  29,2±10, 
PPMS 39,4±11,7, p<0,001); diagnóstico 3,2±5,3 anos depois (RRMS 3,0±5,1, PPMS 4,9±2,5, 
p=0,002); tempo de doença após diagnóstico 9,4±7,2 anos (semelhante RRMS no diagnóstico e 
PPMS); idade atual 42,9±12,4 anos (grupo RRMS no diagnóstico 42,0±12,1, PPMS 52,5±11,3, 
p<0,001); EDSS atual 2,5 (RRMS 2.0, PPMS 6.0); proporção feminino:masculino é 2,5:1 (RRMS 
semelhante, PPMS 1,1:1, p<0,05); no diagnóstico RRMS 90,6%, SPMS 0,9%, PPMS 8,6%; 9,5% dos 
RRMS encontravam-se em SP na inclusão (nomeadamente os com mais idade no diagnóstico 
e/ou atualidade ou tempo de doença mais prolongado). PPMS mais frequente em doentes 
diagnosticados mais tardiamente (p<0,001), onde aumenta também ligeiramente a proporção 
de mulheres na PPMS. Nas últimas décadas: novos casos mostram estabilidade na proporção de 
géneros e tipos de doença; idade nos primeiros sintomas e no diagnóstico aumentou 
ligeiramente, tempo entre eles diminuiu ligeiramente. Proporção sob DMT (Maio 2014): global 
84,5%; atualmente RRMS 90,4%; SPMS 70,8%; PPMS 36,8%; progressivas agregadas 48%. Tipo 
de DMT, amostra global: interferões 56,5%, GA 18,4%, Natalizumab 11,6%, Fingolimod 9,7%. 
Global: economicamente ativos 61,5%, desemprego 13,5%, 74,1% dos não activos estão 
reformados por doença. Gravidezes após diagnóstico em 15% mulheres. Casos com história 
familiar positiva 7,8%.  
Discussão e conclusões: Incluída cerca de 10% da população portuguesa. Resultados congruentes 
com dados internacionais. Elevada proporção sob DMT, mesmo EDSS alto e formas progressivas. 
Terapêuticas de segunda linha sub representadas. Doentes jovens e com doença ligeira com vida 
económica ativa; restantes essencialmente reformados por doença.   
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Introduction and background 
  
Surveys and registries are essential instruments to gather data on multiple aspects of a disease, 
including: its epidemiology; its clinical course (especially in the long-term); the provision of 
treatments, services and supplies for it within a given region; the effectiveness, efficiency (cost-
effectiveness) and safety  of treatments or other interventions (namely in the long-term); the 
implementation of guidelines relating to care and treatment; and its quality of life, burden of 
symptoms and socioeconomic aspects from the patient’s perspective, just to name a few 
(Flachenecker 2008, Flachenecker 2014). The information provided by these studies is useful not 
only to ameliorate the quality of care of patients, but also for society in more general terms, by 
increasing the understanding and knowledge about diseases and allowing authorities and 
relevant parties to make better informed, more effective, decisions about them. Surveys and 
registries are also especially important when rare, complex and/or costly diseases, Multiple 
Sclerosis (MS) belonging to the group that satisfies these three conditions, are concerned. 
In MS, a number of well-known registries exists in the developed world. Many of them, or all of 
them if we consider them globally, have been extremely important to understand this complex 
disease in many ways. They clarified many aspects of the natural history, certain long-term 
effects of treatments, and also the standards of care. In this, as in other diseases, registries are 
also increasingly becoming instruments that health authorities use (at the same time as 
investigators) to plan and control many aspects of the health care. In certain countries, 
authorities determine the obligatory introduction of patients in registries for certain diseases 
(one example is the Danish MS Treatment Registry) (Flachenecker 2014).  
As it would be expectable, the majority of existing registries on MS, including the most important 
ones, are based on healthcare services, namely MS centers, although some of them also cross 
their data with information coming from other sources. This last strategy permits to attain a high 
level of ascertainment of cases at the national level (Danish MS Registry and New Zealand’s 
cross-sectional national prevalence study of 2006). Other studies such as NARCOMS (North 
American Research Committee on MS) registry, initiated in 1996 by the North-American 
Consortium of MS Centers, are patient-based. NARCOMS is a long-term project to promote and 
facilitate clinical and epidemiological research in MS. After informed consent, patients are 
enrolled into the registry and report subsequent updates or any changes in health state or 
treatment. These data include demographics, healthcare insurance, therapies, healthcare 
services used, disability, handicap and quality of life. Since the diagnoses of MS are unverified, 
Paulo Alegria  Master’s Dissertation  2015  Page 13 
Faculdade de Ciências Médicas, Universidade Nova de Lisboa  College of Professional Studies, Northeastern University 
 
self-reported diagnoses of registry participants are compared to physician-reported diagnoses 
and with those based on reviews of medical records. Apart from the NARCOMS Registry, several 
small and uncoordinated MS registries and databases are available within the United States, but 
one national harmonized data collection system does not exist (Flachenecker 2008, Hurwitz 
2010).  
Some studies constitute international collaborations (like EDMUS and MS-base), but the 
majority has a national dimension, with various levels of ascertainment (Danish MS Registry; 
Danish MS Treatment Registry; Swedish MS Registry; Norwegian MS Registry and biobank; 
Italian MS Database Network and German MS Registry). The Danish MS Registry is considered 
de gold standard of MS registries. It has, since January 1, 1949, been continuously updated with 
collected data on virtually all known new cases of MS in Denmark. The sources of notification 
are all 22 neurological departments in Denmark, private neurology and general practitioners, 
rehabilitation hospitals, the Danish MS Society, neuropathological departments, the National 
Patient Registry and the National Registry of Causes and Death (Flachenecker 2008). Only three 
neurologists have been involved in classification, ensuring a certain degree of homogeneity 
(Koch-Henriksen 2012). With the introduction of immunomodulatory therapy in Denmark in 
1996, all patients starting treatment were also registered mandatorily in a Danish MS Treatment 
Registry and followed prospectively. The Danish registries include clinical data, neurological 
examination and standard laboratory tests that are regularly updated (Flachenecker 2008). They 
allow analysis of trends in incidence, prevalence, survival and cause-specific mortality and 
provide samples of patients for research, case-control studies and prospective studies 
(Bronnum-Hansen 2011). The Swedish Registry was introduced in 1997 and is widely used in 
neurology clinics all over the country by neurologists when counselling patients. It includes 
variables such as age at onset, gender and clinical parameters. (Westerlind 2014). The 
Norwegian MS Registry and Biobank besides gathering clinical and epidemiological data also 
collects biological samples, including blood, CSF and brain tissue. This registry has a key 
component in recruiting patients into the large international case–control study to investigate 
environmental risk factors in MS (Myhr 2012). The Italian MS Database Network is the first 
Italian MS registry that is based on a user-friendly, electronic MS patient monitoring system. 
Several specialised MS centres were selected and agreed on a standardized protocol. Each study 
site has a neurologist responsible for the quality and consistency of data and then a Scientific 
Advisory Board is responsible for the analysis, approval and validation of the database 
(Flachenecker 2008). In Germany, there was a study with a 2-year pilot phase and based on 
experience gained during that phase, some parameters were modified. The survey was not 
population-based, relying mainly on data provided by health institutions (Flachenecker 2008). 
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Some studies follow local cohorts prospectively with a high level of detail in information 
collected (London, Ontario database; British Columbia MS database; New York State MS 
Consortium database; Department of Veterans Affairs registry; North American Research 
Committee on MS) ( Hurwitz 2010). The majority of the databases have a prospective follow-up, 
although some important studies were transversal studies (New Zealand’s cross-sectional 
national prevalence study of 2006).  
 
In the European Union, healthcare for, as well as the socioeconomic conditions of, MS patients 
differs greatly across countries. Different registries and databases also differ in terms of 
objectives, time, and resources spent for registration and analytical preferences, and they are 
not available everywhere. In the intent to tackle those disparities, the European Commission 
financed a project of the international consortium European MS Platform (EMSP). This project, 
called EUReMS (European Register for MS), was set up in 2010 and its general aim is to establish 
a European-wide platform for systematic analysis and comparison of longitudinally collected MS 
data in Europe. It involves both scientists and patient organizations. One of EUReMS’ principles 
is that it should be built on already existing national or regional MS registries and databases, 
harmonizing and merging them. In a systematic survey of the MS registries in Europe in 2012, 
20 registries were identified (Table 1). As the authors of the survey stated, these registries 
differed widely for objectives, structure, collected data, and for patients and centers included. 
Despite this heterogeneity, common objectives of the registries were epidemiology (n=10), long-
term therapy outcome (n=8), healthcare research (n=9) and support/basis for clinical trials (n=8). 
Less frequent registry aims were cost and cost-effectiveness of treatment (n=5), quality 
management of healthcare (n=5), and gathering data (n=1). All registries included patients with 
MS according to the McDonald criteria. In addition, six registries applied Poser criteria, and eight 
registries also collected data on patients with clinically isolated syndromes (CIS). A Catalan 
registry was specifically designed for CIS patients. The majority of registries was hospital-based 
(n=10, 77%), and five (38%) population-based, with three registries being hospital- and 
population-based together. In three registries, patient lists from MS societies were used either 
exclusively (n=1) or in combination with the above-mentioned sources of data collection. Most 
registries (n=9, 69%) intended to capture all MS patients in the country, whereas four registries 
(31%) attempted to collect data on representative subsets (regions) of patients (Croatia, Italy, 
Switzerland and United Kingdom). According to EUReMS, a pan European database should focus 
on four missions: MS epidemiological and clinical surveillance; long-term efficacy, safety and 
cost-effectiveness of MS disease-modifying and symptomatic treatments; provision and quality 
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of healthcare services; and quality of life, the burden of symptoms and socioeconomic aspects 
from the patient’s perspective. 
No reference is made to Portugal in this study. There is not, in our country, at least at a 
multicentric level, a registry or even a wide cross-sectional characterizations of the state of this 
disease, these patients and their treatment. In fact, demographic, epidemiological or clinical 
data about MS at a regional or national level is scarce in Portugal. A population-based 
prospective study conducted over a period of five years and published in 2006 revealed a 
prevalence of 46.3/100 000 in the district of Santarém (De Sá 2006, De Sá 2010), and in 2010 a 
national transversal study using a survey determined a self-reported MS prevalence in 
continental-Portugal, among adults of 54/100 000 and an estimated number of patients of 4287 
(varying between 2700 and 5875) (EMCode, DGS). We did not find other relevant publications 
of national level about general aspects of the disease in our country.  
 
Having this in mind, the author of this dissertation, coordinating a group of other investigators,   
set up the here presented PORT-MS study with the primary objective of knowing the 
characteristics of the Portuguese MS population in terms of demography, main disease 
milestones, present clinical state, general aspects of treatment and socioeconomic status, 
including education and employment data. Secondary objectives of this study were: to identify 
any eventual focus of high or low prevalence in the Portuguese territory; to collect data on 
pregnancy in female MS patients; to collect data on familial cases of MS; to know the proportion 
of patients that has participated in interventional trials; to identify any possible asymmetries in 
demography, clinical characteristics, milestones of the disease or standards of diagnosis and 
care between Portugal and other countries and contribute to the explanation or correction of 
these asymmetries; to foster the development of a prospective national registry and eventually 
contribute to a European database. 
 
Due the extension of this study and the limit date for the presentation of this dissertation, here 
I present the design and implementation of the PORT-MS study and also the first results. The 
analysis of all the data gathered will continue throughout the next few months and sometimes 
it may be visible in this dissertation that the analysis of some results seems somewhat 
incomplete. Also, in view of the bilingual nature of this study, sometimes there is some 
Portuguese phrasing that I was unable to translate.  
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Table 1. MS registries in Europe. (Adapted from: Multiple Sclerosis Journal 2014, 
Vol. 20(11) 1523– 1532.) 
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Methods 
The complete protocol of this study is presented in the Appendices section of this document. 
Study rationale and objectives, design and procedures, population and sample, informed 
consent and regulatory aspects, CRF and publication policy are detailed there. Here I present 
only a brief summary and documentation or data produced after protocol submission 




MS patients fulfilling McDonald 2010 criteria in seven participating centers (Table 2 and Figure 
1) were sequentially recruited in the outpatient clinics, day-hospital and Neurology wards, from 
May 2014 until November 2014 (this constitutes the “phase 1” of this project). In order to avoid 
selection bias, participating physicians were encouraged to include all patients with MS seen in 
their practice.   
 
 
Table 2. Identification of the MS Centers that participated in the PORT-MS study (phase 1).  
 
 Serviço de Neurologia, Hospital de Braga, Braga, Portugal  
 Serviço de Neurologia, Centro Hospitalar de São João, Porto, Portugal  
 Serviço de Neurologia, Centro Hospitalar do Porto – Hospital de Santo António, 
Porto, Portugal  
 Serviço de Neurologia, Centro Hospitalar Universitário de Coimbra, Coimbra, 
Portugal  
 Serviço de Neurologia, Hospital Beatriz Ângelo, Loures, Portugal  
 Serviço de Neurologia, Centro Hospitalar de Lisboa Norte – Hospital de Santa Maria, 
Lisboa, Portugal  
 Serviço de Neurologia, Centro Hospitalar de Lisboa Central – Hospital de Santo 
António dos Capuchos, Lisboa, Portugal 
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Collected Data  
 
A systematized Case Report Form (CRF) collecting retrospective and present data directly from 
the clinical file, the patient and the patient’s physician was applied (cross-sectional study). Date 
and place of residency at birth, at first symptoms and at diagnosis of MS, gender, migrations 
abroad during life, disease clinical course, current (May 2014) treatment and EDSS, education 
(International Standard Classification of Education - ISCED 2011), status of employment in the 
week preceding the CRF filling (International Classification of Status of Employment - ICSE 1993), 
need for a caregiver, involvement in clinical trials, familial MS and pregnancy.  
Data sets were coded using a unique key designed to allow us to identify repeated cases due to 







Figure 1. Geographical localization of the 7 participating centers in phase 1 of the PORT-MS study. 
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Phase 1 of this study, which occurred between the mentioned dates, was expected to include 
500 patients, which was accomplished.  
We used SPSS software for Windows, version 20 (SPSS Inc., Chicago, IL, USA) to calculate 
descriptive and inferential statistics. Parametric and Non-Parametric tests were used. 
Comparisons were labeled as statistically significant at the conventional p-value of less than 
0.05. 
 
Ethics and other approvals  
 
According to the Portuguese law concerning the treatment of healthcare data and clinical 
investigation, this study was submitted to the [National Committee for Data Protection] (CNPD, 
Comissão Nacional de Proteção de Dados) and approved by this organization. The corresponding 
file number is 5288/2014 and the approval number is the 6761/2014. This data is public and 
available at the CNPD’s internet site.  
 
Although this study is not a Clinical Trial, according to the Portuguese law on clinical investigation 
(Law number 21/2014, dated the 16th April 2014), this study was submitted to the local ethics 
committee of each of the hospitals (CES, Comissão de Ética para a Saúde, in the Portuguese 
acronym and designation) where this study run (and is still running), and approved by each of 
them. Figure 2 shows one example of these approvals for the sake of proof.  
Our procedures also respected the Declaration of Helsinki and the guidelines on Good Clinical 
Practice (GCP) of the International Conference on Harmonisation of Technical Requirements for 
Registration of Pharmaceuticals for Human Use (ICH), notably in terms of collection of consent 
from patients (the respect for these norms is integrated on the Portuguese and European law 
on Clinical trials). 
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Figure 2. Example of approval of the PORT-MS study by a local ethic committee (in this 
case corresponding to the Hospital Beatriz Ângelo). 
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Results  
General aspects of the database 
 
The MS centers of seven hospitals collaborated to this database (Table 2 and Figure 1). These 
hospitals are distributed throughout the northern, central and southern coastal side of the 
Portuguese continental territory. Six of them are University hospitals, one of them is not. Five 
of these University hospitals are classified as “tertiary” or “central” hospitals, and they hold the 
five biggest MS centers in Portugal. The other two hospitals are considered more like “regional” 
hospitals. Together, these institutions may follow more than half of the Portuguese MS patients, 
but the number included until now in this database is partial in each of them, globally 
equilibrated between institutions but reflecting, at the same time, the total number of patients 
each of them has on follow-up. 
 
The patients that eventually refused to participate in the study were not registered but we are 
not aware of any, so they must have been exceptional at most (in view of the number of 
investigators involved, we theoretically admit that the coordinating investigators of the study 
might have missed some exceptional cases).  
 
The first CRF was filled in May 2014, the last one in November of the same year. No repeated 
patients were detected in the 568 patients initially included but seven patients were excluded 
due to incomplete data in six cases and incongruent data in one case.  
 
561 patients were confirmed as fulfilling the minimum requirements in terms of data available 
and congruency of data. Considering the estimated total number of 5000 to 6000 patients with 
MS in Portugal, this database contains around 10% of the Portuguese patients.  
 
 
General characteristics of the patients and of their disease 
 
 
The clinical type of disease at disease onset (first symptoms) and at diagnosis was asked in a 
single question that admitted the hypothesis of start as RRMS and diagnosis still in RRMS or the 
hypothesis of start as RRMS but already diagnosed in SPMS. Of course, the assumption of a 
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certain clinical profile at disease onset (first symptoms) is, in the great majority of patients, 
based in the anamnesis. We didn’t ask specifically if a patient that was assumed to start as a 
progressive relapsing form was still having relapses at diagnosis. We opted for distinguishing 
progressive relapsing patients from not relapsing ones to more accurately identify a group of 
progressive patients with less bias.  
The clinical type of MS at disease onset and diagnosis is shown in Table 3. 
 
 
Table 3. Clinical type of MS onset and diagnosis. 
 
 
The clinical type of disease at disease onset (first symptoms), derived from the previous table, 
is shown in Table 4 and Figure 3 (we excluded a few patients that were still not definitively 




PP w/o relapses 6,8% 
PP w/ relapses 1,3% 
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Figure 3. Clinical type of MS at disease onset (after excluding cases with still ambiguous profile). 
 
 
First symptoms of disease occurred at the age of 30,2±10,5 years-old. (min 5; max 70). The first 
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Time elapsed from first symptoms to diagnosis was 3,2±5,3 years in our sample.  
 
The clinical type of disease at diagnosis is shown in Table 5 and Figure 5 (we excluded a few 




PP w/ or w/o relapses 8,1% 






Figure 5. Clinical type of MS at diagnosis (after excluding cases with still ambiguous profile). 
 
Mean age at diagnosis was 33,4±11,1 years-old (min: 5; max: 70). The diagnosis of MS occurred 









PP w/ or w/o
relapses
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Figure 6. Decade of life of patients at diagnosis.  
 
 
The time of disease evolution from diagnosis to inclusion for our total sample is 9,4±7,2 years 
(min: 0; max: 36,2; median: 7,5 years).  
Total time of disease evolution from first symptoms to inclusion of patients in our sample is 
12,6±9,2 years (min: 0,2; max: 49,8 years).  
 
Time from diagnosis to inclusion of group “RRMS at diagnosis” is 9,6±7,3 years, and of PPMS 
patients it is 8,1±6,4 years (p=0,2, Independent-samples Mann-Whitney U test). 
 
Of our 508 patients that were in RR phase by the time of diagnosis, 9,5% reached SPMS by 
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Figure 7. Patients that reached SPMS by time of CRF filling, having been diagnosed in RRMS phase at diagnosis.  
 
The clinical types of MS at inclusion (or current type of MS or, type of MS at present time) is 
shown in table Table 6 and Figure 8. 
 
RR 82% 
SP started after diagnosis 8,6% 
SP already at diagnosis 0,9% 
PP w/ or w/o relapses 8,0% 
doubtful 0,5% 













SP started after diagnosis
SP already at diagnosis
PP w/ or w/o relapses
doubtful
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Figure 9. Current decade of life of patients (at inclusion).  
 
 
Figure 10. Proportions of current decade of life of patients (at inclusion).  
 
Dates of birth of patients are comprised between June 1938 and September 1997 (median 
August 1972).  
 
 
Paulo Alegria  Master’s Dissertation  2015  Page 28 












70,8% (n=397) of patients of our sample are female (29,2% male, n=164), which is equivalent to 




Place of birth 
 
92,9% of the patients were born in Portugal. Forty patients were born outside de country, 
essentially in countries belonging to the European Union, in other countries historically 
associated with Portuguese emigration, or in Portuguese ex-colonies. Around half of these cases 
correspond to countries of higher latitude or traditionally considered of higher MS prevalence 
(Table 7). All the patients born in Portugal are of Portuguese nationality, as are 20% (seven cases) 
of those born abroad.  
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Table 7. Place of birth of the 40 patients 
(7,1% of our total patients) that were 





98,9% of the patients in the database are white, five patients are black (0,9%), and one case is 




Analysis of age at first symptoms across the last decades, across clinical 
types of disease and across genders 
 
 
Age at first symptoms (Figure 12) has slightly increased over the last few decades (p=0,009, 
Independent-Samples Kruskal-Wallis test).  
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Figure 12. Mean age at first symptoms for diagnosis occurring in each decade in time. 
 
 
Age at first symptoms of group “RRMS at diagnosis” was 29,3±10 years-old (n=508, CI95%: 
[28,5;30,2]) versus 39,4±11,7 years-old (n=38, CI95%: [35,6;43,3]) in PPMS patients (p<0,001, 
Independent-samples Mann-Whitney U test) (Table 8, Figure 13Figure 13. Age at first symptoms 
by clinical type of MS (RRMS versus PPMS).). From the group of patients RRMS at diagnosis, 
those that were already in SPMS at inclusion had started the disease at the same age than those 
that remained in RRMS at inclusion.  
 
 N 
Age at first symptoms 
(years-old) 
All 561 30,2±10,5 




PPMS w/ relapses 7 42,1±9,7 
PPMS together 45 39,9±11,3 
SPMS at diagnosis 5 28,6±8,5 
SPMS at inclusion  
(RRMS at diagnosis) 
48 30,62±10,6 
RRMS at inclusion 458 29,22±9,9 
All SPMS at inclusion 53 30,4±10,4 
Table 8. Age at first symptoms for each of the clinical subtypes.  
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Figure 13. Age at first symptoms by clinical type of MS 
(RRMS versus PPMS). 
 
 
Men reported first symptoms at an earlier age than women. Although small, this difference 
attains statistical significance when we analyze the whole sample or only RRMS at diagnosis. The 
difference is more marked in PPMS (without relapses), but here statistical significance is not 




(N) age at first 
symptoms 
Female 
(N) age at first 
symptoms 
p 
All (164) 28,6±9,4 (396) 30,9±10,9 
0,021 (Independent-
samples Mann-
Whitney U test) 
RRMS at diagnosis (144) 27,6±8,9 (363) 30,0±10,3 
0,015 (Independent-
samples Mann-
Whitney U test) 
PPMS 
(w/o relapses) 
(18) 35,8±11,2 (20) 42,7±11,3 
n.s. (Independent-
samples T test) 
Table 9. Age at first symptoms for male and female gender in selected clinical subtypes.  
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Analysis of time from first symptoms to diagnosis across the last decades, 
across clinical types of disease and across genders 
 
If we only consider from 1991 onwards (we have only 30 patients diagnosed before that date in 
our database), time from first symptoms to diagnosis seems to has slightly reduced throughout 
these last decades. There is no significant statistical difference between groups, though 
(Independent-Samples Kruskal-Wallis test) (Table 10). 
 
 
Table 10. Time elapsed from first symptoms to diagnosis for 
diagnoses occurring in each decade in time. 
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Time from first symptoms to diagnosis of “RRMS at diagnosis” cases was 3,0±5,1 years (n=508, 
CI95%: [2,6;3,5]) versus 4,9±2,5 years (n=38, CI95%: [2,8;7,0]) in PPMS patients. There is a 
statistically significant difference between these groups (p=0,002, Independent-samples Mann-
Whitney U test) (Figure 15).  
 
 
Figure 15. Time elapsed from first symptoms to diagnosis in RRMS 
versus PPMS cases. 
 
 
Those that were considered to have started in RRMS form but were already in SPMS at diagnosis 
reported a much higher lapse of time between first symptoms and diagnosis than patients that 
were still in RRMS at diagnosis (p=0,03, Independent-samples Mann-Whitney U test). 
For patients in RRMS at diagnosis, those that later evolved to SPMS until inclusion also reported 
an already longer time from first symptoms to diagnosis than those RRMS at diagnosis that 
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 N 
First symptoms to diagnosis 
(years) 
All 561 3,2±5,3 




PPMS w/ relapses 7 4,3±3,3 
PPMS together 45 4,8±6,1 
SPMS at diagnosis 5 9,98±6,1 
SPMS at inclusion  
(RRMS at diagnosis) 
48 7,3±8,3 
RRMS at inclusion 458 2,5±4,4 
All SPMS at inclusion 53 7,6±8,1 
Table 11. Time from symptoms to diagnosis ion each clinical type of disease.  
 
There are no statistical differences in the elapsed time from first symptoms to diagnosis 












All (164) 3,1±5,1 (396) 3,3±5,4 
n.s. (Independent-
samples Mann-
Whitney U test) 
RRMS at diagnosis (144) 3,0±5,3 (363) 3,0±5,1 
n.s. (Independent-
samples Mann-
Whitney U test) 
PPMS 
(w/o relapses) 
(18) 3,4±3,5 (20) 6,3±8,1 
n.s. (Independent-
samples Mann-
Whitney U test) 
Table 12. Time from symptoms to diagnosis ion gender for selected clinical types of disease. 
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Analysis of age at diagnosis across the last decades, across clinical types of 
disease and across genders 
 
Age at diagnosis (Erro! A origem da referência não foi encontrada.) is slightly higher in these 
last decades (p=0,035, Independent-Samples Kruskal-Wallis test). 
 
  
Figure 16. Mean age at diagnosis for diagnosis ocurring in each decade. We have relatively few cases 
corresponding to the pre CT scan / MRI era.  
 
Age at diagnosis of “RRMS at diagnosis” cases was 32,3±10,4 years-old (n=508, CI95%: 
[31,4;33,2]) versus 44,2±11,6 years-old (n=38, CI95%: [40,4;48,1]) in PPMS patients (p<0,001, 
Independent-samples Mann-Whitney U test) (Figure 17). 
 
Figure 17. Age at diagnosis of group “RRMS at diagnosis” 
vs PPMS (without relapses). 
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Inside patients in “RRMS at diagnosis”, those that later developed SPMS before inclusion were 
already diagnosed at a later age than the rest of the group “RRMS at diagnosis”, that’s to say, 
than “RRMS at diagnosis” that remained in RRMS at inclusion (38,0±10,4 vs 31,8±10,3, p<0,001, 
Independent-samples Mann-Whitney U test) . As a matter of fact, they have been diagnoses at 
the same age than a small group of patients that have been diagnosed already in the SPMS form.  
 
 N 
Age at diagnosis 
(years-old) 
All 561 33,4±11,1 




PPMS w/ relapses 7 46,4±11,9 
PPMS together 45 44,6±11,6 
SPMS at diagnosis 5 38,4±9,99 
SPMS at inclusion  
(RRMS at diagnosis) 
48 38,0±10,4 
RRMS at inclusion 458 31,8±10,3 
All SPMS at inclusion 53 38,0±10,3 





Men are diagnosed at a lower age than women for the whole sample, RRMS at diagnosis and 
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(N) Age at diagnosis 
(years-old) 
Female 
(N) Age at diagnosis 
(years-old) 
p 




Whitney U test) 




Whitney U test) 
PPMS 
(w/o relapses) 




Whitney U test) 
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Analysis of total follow-up after first symptoms and after diagnosis across 
clinical types of disease and across genders (includes progression to SPMS) 
 
 
Time from diagnosis to inclusion of group “RRMS at diagnosis” is 9,6±7,3 years, similar to that 
of PPMS patients, which is 8,1±6,4 years (p=0,2, Independent-samples Mann-Whitney U test).  
Mean time of evolution from diagnosis to inclusion of patients that evolved to SPMS after 
diagnosis is the double of those who did not (16,5±7,2 years versus 8,8±6,9 years) (Erro! A 
origem da referência não foi encontrada.). We had seen before that, although these patients 
had presented the first symptoms at the same age as others “RRMS at diagnosis”, they already 
had more time of interval between first symptoms and diagnosis and had been diagnosed at a 










All 561 12,6±9,2 9,4±7,2 
RRMS at diagnosis 508 12,6±9,3 9,6±7,3 
PPMS 
(w/o relapses) 
38 12,98±8,4 8,1±6,4 
PPMS w/ relapses 7 13,0±7,4 8,8±8,5 
PPMS together 45 12,98±8,2 8,2±6,7 
SPMS at diagnosis 5 19,5±8,7 9,5±8,2 
SPMS at inclusion 
(RRMS at diagnosis) 
48 23,8±10,98 16,5±7,2 
RRMS at inclusion 458 11,3±8,1 8,8±6,9 
All SPMS at inclusion 53 23,4±10,8 15,9±7,5 
Table 15. Evolution of disease departing from first symptoms and from diagnosis for each clinical course.  
 
 
As stated above, of our 508 patients that were in RR phase by the time of diagnosis, 9,5% 
reached SPMS by inclusion (Figure 7) (8,4% of males in RRMS at diagnosis and 9,9% of women). 
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Table 16 gives us a perspective of the proportion of patients that progresses to SPMS along the 




Corresponding number of patients 
we have in our database 
Proportion of patients that reached 
SPMS in the meanwhile 
≤5 years N=171 2,3% 
≤7 years N=237 3% 
≤10 years N=302 3,3% 
≤15 years N=? 5% 
≤20 years N= 458 6,6% 
All N=508 9,5% 





Figure 19. Time of evolution after diagnosis for patients 
initially diagnosed in RRMS that remained in RRMS at 
inclusion (left or “Não”) versus those that evolved to 
SPMS in the meanwhile (right or “Sim”). 
 
 
There are no statistical differences in times of follow-up between genders in our sample (Table 
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All (164) 12,8±9,1 (396) 12,6±9,2 
n.s. (Independent-
samples Mann-
Whitney U test) 
RRMS at diagnosis (144) 12,8±9,2 (363) 12,5±9,3 
n.s. (Independent-
samples Mann-
Whitney U test) 
PPMS 
(w/o relapses) 
(18) 11,6±7,2 (20) 14,2±9,3 
n.s. (Independent-














All (164) 9,7±6,9 (396) 9,3±7,4 
n.s. (Independent-
samples Mann-
Whitney U test) 
RRMS at diagnosis (144) 9,8±6,95 (363) 9,5±7,4 
n.s. (Independent-
samples Mann-
Whitney U test) 
PPMS 
(w/o relapses) 
(18) 8,2±6,1 (20) 7,9±6,9 
n.s. (Independent-
samples Mann-
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Analysis of age at inclusion across clinical types of disease and across 
genders (includes progression to SPMS) 
 
Age at inclusion is considerably higher for PPMS than for group “RRMS at diagnosis” (52,5±11,3 
years-old versus 42,0±12,1 years-old, respectively, p<0,001, Independent-samples Mann-
Whitney U test) or for group “RRMS at inclusion” (52,5±11,3 years-old versus 40,7±11,6 years-
old, respectively, p<0,001, Independent-samples Mann-Whitney U test) (Table 19). 
 
Patients “RRMS at diagnosis” that remain in “RRMS at inclusion” are 40,7±11,6 years-old at 
inclusion, whereas “RRMS at diagnosis” that evolved to SPMS at inclusion are 54,5± 10,1 





Age at inclusion 
(years-old) 
All 561 42,9±12,4 




PPMS w/ relapses 7 55,1±10,6 
PPMS together 45 52,9±11,1 
SPMS at diagnosis 5 47,8±9,9 
SPMS at inclusion  
(RRMS at diagnosis) 
48 54,5± 10,1 
RRMS at inclusion 458 40,7±11,6 
All SPMS at inclusion 53 53,9±10,2 
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Figure 20. Age at inclusion for patients initially 
diagnosed in RRMS that remained in RRMS at inclusion 
(left or “Não”) versus those that evolved to SPMS in the 
meanwhile (right or “Sim”). 
 
Men with PPMS (without relapses) included in our sample are younger than women (Table 20). 
We have seen before that they started first symptoms are a slightly younger age (statistically 
n.s.) and that they also were diagnosed at an earlier age than their female counterparts. Time 
from first symptoms to diagnosis and follow-up from diagnosis to inclusion is the same, though 
(statistically). We have a little number of patients in these categories and this data should be 




(N) Age at inclusion 
(years-old) 
Female 
(N) Age at inclusion 
(years-old) 
p 
All (164) 41,5±11,2 (396) 43,6±12,9 
n.s. (Independent-
samples Mann-
Whitney U test) 
RRMS at diagnosis (144) 40,4±10,8 (363) 42,6±12,6 
n.s. (Independent-
samples Mann-
Whitney U test) 
PPMS 
(w/o relapses) 




Table 20. Age at inclusion for males and females.  
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Analysis of the proportions between clinical types of MS across the last 
decades in time, across different ages at diagnosis and across genders 
 
The number PPMS (without relapses) compared to RRMS (we have very few patients diagnosed 
in the groups “RR already in SPMS” and “PPMS with relapses”), at diagnosis, is higher in patients 
born is more distant decades (then, older patients) that in patients born more recently as is 
shown in Table 21. 
 
 




The proportion of PPMS diagnosed in each decade in time seems, on the other hand, stable in 
the last few decades (p=0,29, Pearson Chi-Square test, Cochran criteria verified after joining 
together the decades of 1971-80 and 1981-90) (Figure 21).  
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The apparent dissociation of the two precedent results is explained by the fact that the 
proportion of patients with PPMS is higher in patients diagnosed later in life (p<0,001, Pearson 
Chi-Square test, Cochran criteria verified after joining together the first and second decades of 
life, and excluding the 7th decade of life, due to low number of patients in those groups) (Erro! 




Figure 22. Proportion of patients diagnosed with PPMS versus RRMS in diagnosis occurring in each decade of life. 
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 Males Females   
Proportion of RMMS 
at disease onset 
88,4% 92,7%  
% of PPMS (w/o 
relapses) at disease 
onset  
11% 5%  
Proportion of RRMS at 
diagnosis that had 
progressed to SPMS at 
inclusion 
8,4% 9,9%  




Analysis of gender across the last decades in time, across different ages at 
diagnosis and across clinical types of disease 
 
The proportion of male to female seems globally stable when we analyze it by decade of birth 
of patients (p=0,08, Pearson Chi-Square test, Cochran criteria verified after joining together the 
first 2 decades, where we have relatively few cases) (Figure 23). 
It’s also stable when we analyze it by decade in time at which the diagnosis occurred (see Figure 
24, where we should look essentially to the last 3 decades, where we have a more representative 
number of patients).  
When we analyze this same proportion by decade of life at which the diagnosis occurred (an 
analysis by age at diagnosis, then), even if apparently, in cases diagnosed later in life, there is an 
increased proportion of females (Figure 25), this is not statistical significant (p=0,1, Pearson Chi-
Square test, Cochran criteria verified after joining together the two decades in both extremes, 
where we have relatively few cases). In fact, in Erro! A origem da referência não foi encontrada., 
if we only look to the decades where we have a more significant number of patients, that 
increase is small.  We will need to review this tendency when we have a bigger number of 
patients in our database. 
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Figure 23. Proportion of male to female by decade of birth of patients (highlighted in red the four decades where we 
have a more representative number of patients). 
 
  
Figure 24.Proportion of male to female by decade in time at which the diagnosis occurred.  
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The analysis of distribution of gender in each type of disease shows a proportion of 2,5 females 
to 1 male in “RRMS at diagnosis” and an almost equilibrated representation of both sexes in 
PPMS (without relapses), with 1,1 females to 1 male (p<0,05, Pearson Chi-Square, Cochran 
criteria verified) (Figure 26).  
  












PPMS w/ relapses Low number of patients 
PPMS together 1,4:1 
SPMS at diagnosis Low number of patients 
SPMS at inclusion  
(RRMS at diagnosis) 
3:1 
RRMS at inclusion 2,5:1 
All SPMS at inclusion 3,1:1 
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The exact value of EDSS in May 2014 was possible to obtain for 465 patients (83% of the total 
patients). Median EDSS for the 465 patients with exact EDSS available is 2,5 (P25: 1,0; P75: 5,0). 
Distribution of patients according to the exact EDSS is shown in Figure 27.  
 
 




The class of EDSS was obtained for all patients as predefined in the CRF and essentially taking 
ability to walk in consideration. Distribution of patients by these classes of EDSS is shown in 
Figure 28.  
 
  
Figure 28. Distribution of patients by classes of EDSS in May 2014. 
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For the 465 patients for whom we have an exact value of EDSS available, the relation between 
the current median EDSS and the year of birth (or current age), and between current median 
EDSS and both time of disease evolution since first symptoms and time of disease evolution 
since diagnosis, is shown in Figure 29and Figure 30 respectively. Older patients show a tendency 
to higher EDSS values (rho=0,44, p<0,001, Sperman’s correlation), as do patients with longer 
elapsed times since first symptoms (rho=0,45, p<0,001, Sperman’s correlation), or diagnosis 
(rho=0,40, p<0,001, Sperman’s correlation). 
 
  
Figure 29. Relation between the median EDSS and age at the day of CRF filling, and mean age of the patients for 




Figure 30. Relation between the median EDSS and the time of evolution since first symptoms and the time of 
evolution since diagnosis. 
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For the whole population of our database, the distribution by EDSS classes according to decade 
of birth renders similar results (Figure 31), as older patients show higher representations of 
higher EDSS categories.   
 
  
Figure 31. Distribution of patients by EDSS classes according to decade of birth. Older patients are more 
frequently distributed in higher classes of EDSS.  
 
Although “RR at diagnosis” and PP types have about the same time of evolution after diagnosis 
in our database, we verify that EDSS, at present time, is different between the two groups, as 
shown in Figure 32 and Figure 33 . Analyzing patients in our database for whom we have exact 
EDSS, we ascertain, for the RRMS group (n= 420), a median EDSS of 2,0 (P25: 1,0; P75: 4,0) and 




Figure 32. Distribution of RRMS and PPMS cases in terms of EDSS.   
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Figure 33. Distribution of RRMS and PPMS through 
these the (predefined) classes of EDSS (the sum of the 








84,5% of our total population of patients were under Disease Modifying Treatment (DMT) in 
May 2014 (Table 24). Patients currently in RRMS form are under DMT in 90,4% of cases, as are 
more than half of patients currently in progressive forms (especially those in SPMS).  
 
Population N Under DMT (May 2014) 
All patients 561 84,5% 
RRMS at diagnosis (independently of current clinical type) 508 88,4% 
 Currently in RRMS 459 90,4% 
 RRMS at diagnosis that evolved to SPMS 48 70,8% 
SPMS at diagnosis 5 80% 
All currently in SPMS together 53 71,6% 
PPMS (with or without relapses) 45 44,4% 
All progressive forms together 98 59,2% 
Table 24. Proportion of patients under disease modifying treatment (DMT) in May 2014 for the total population of 
the database and for each subgroup of clinical type of MS. 
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Taking all the population of our database together, patients not under treatment differ from 
those under DMT in that they have been diagnosed at a somewhat older age, they are currently 
older, their disease is slightly longer, but above all in that half of them have progressive forms 
(Table 25). This last fact also means that half of the non-treated patients are in RRMS form, 
which theoretically should be under DMT (see under). Half of the non-treated patients have, 
been treated before. 
 
 
 ALL PATIENTS  
 
Under DMT (May 2014) 
N= 474 (84,5%) 
No DMT (May 2014) 
N=87 (15,5%) 
p 
Age at diagnosis (years-
old) 
32,6 (±10,7) 38,3 (±12,0) p<0,001 
Disease evolution time 
(years) 
9,1 (±6,9) 11,3 (±8,5) n.s. 
Current Age (years-old) 41,7 (±11,9) 49,6 (±13,2) p<0,001 
% Females 71,3% 67,8% n.s. 
% Progressive forms 12,2% 46% p<0,001 
EDSS (median) 2.0 4.0 – 4.5 p<0,001 
No DMT = Patient’s 
decision 
Not applicable 13,3% - 
Were previously on 
(other) DMT 
51% 50% n.s 
Table 25. Comparison of the main characteristics of all patients under disease modifying treatment (DMT) versus all 
patients that were not under DMT (in May 2014).  
 
The 10% (n=44) of patients currently in RRMS are not under treatment been diagnosed at a 
slightly older age and they are currently also slightly older than the 90% treated patients, also in 
part because they have the disease at a longer time, but these differences don’t seem too 
expressive (Table 26). The gender distribution is similar between treated and non-treated 
patients, and EDSS is not that different either. Almost half of the non-treated patients have been 
treated before. 
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15% of the non-treated patients chose not to be treated (n=7). The remaining are not under 
treatment due to medical decision, then. Our data also shows that another 15% of all non-
treated RRMS (n=7) have a very recent diagnosis (2 months or less) which can be an 
explanation per se. We also know that another situation where a substantial part of RRMS are 
not on DMT is when the diagnosis has 20 or more years (Table 27). Then, globally, patients 
with RRMS not treated, in Portugal, they are either in the first 3 months of disease or they 
have more than 10 years of disease. We have no other data to explain the other cases. 
Nevertheless, 75,7% of all these non-treated patients were women, men and women have 
about the same age (45,1±13,8 years-old), they have 11,5±9,2 years of disease evolution after 
diagnosis and their EDSS is distributed from 0,0 to 8,0 in a relatively equilibrated fashion 
without significant differences.  
 
 CURRENTLY RRMS (N=459)  
 
Under DMT (May 2014) 
N= 415 (90,4%) 
No DMT (May 2014) 
N=44 (9,6%)* 
p 
Age at diagnosis (years-
old) 
31,6 (±10,2) 33,5 (±11,1) n.s. 
Disease evolution time 
(years) 
8,7 (±6,6) 10,5 (±8,8) n.s. 
Current Age (years-old) 40,3 (±11,3) 43,9 (±13,4) n.s. 
% Females 71,3% 72,7% n.s. 
EDSS (median) 2.0 2.5 n.s. 
No DMT = Patient’s 
decision 
Not applicable 15% - 
Were previously on 
(other) DMT 
49% 47,7% n.s. 
* Of these, 7 cases (15%) had less than 3 months of diagnosis (none of them coinciding with the 15% that refused 
treatment). 
Table 26. Comparison of the main characteristics of patients currently in RRMS that were under disease modifying 
treatment (DMT) versus those not under DMT (in May 2014).  
 
Table 27 also shows us that (for patients on DMT) it’s between the end of the first year of 
diagnosis and the start of the 3rd year after diagnosis that many (around 40%) RRMS patients 
change DMT (for the first time), and that around 40% of the patients with more than 10, 15 and 
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even 20 years of disease evolution, always stayed of the first DMT. The remaining 20% change 
DMT somewhere in the middle. As stated before, it’s in the second decade of disease evolution 
that some RRMS patients quit DMT, which is even more pronounced after the 20th year of 
disease after diagnosis. This table must, of course, be interpreted in the particular context of the 
availability of therapies. This availability is homogenous in Portugal because almost all patients 
are treated in public hospital with very similar availability (some discrepancies exist in practice 
due to different administrative procedures to have access to some (more expensive) therapies). 
In 2014, in Portugal, despite approval by the EMA of drugs like dimethyl fumarate, teriflunomide 
and alemtuzumab, none of these is widely available in Portuguese public hospitals.  
 
PATIENTS THAT REMAIN IN RRMS 
Years after diagnosis N Under DMT 
…of which had been on 
other DMT before (%) 
<=1 35* 80% 0% 
1-2 36 88,9% 15,6% 
2-3 28 96,4% 44,4% 
3-4 29 100% 41,4% 
4-5 39 94,9% 51,4% 
5-10 125 93,6% 56,4% 
10-15 74 86% 60,8% 
15-20 50 96% 62,5% 
>20 30 63,3% 59,1% 
* All the patients not under DMT in this group (7 patients, 20% of the group) had less than 3 months of diagnosis. 
Table 27. Percentage of patients currently on DMT and that had (other) DMT before in each interval of disease 
evolution time. 
 
For what concerns progressive forms, our data are unable to distinguish between patients with 
progressive forms of the disease under DMT and not on DMT (Table 28). We know that in 10% 
of the non-treated cases it was the patient’s decision that apparently determined that option, 
at that half of the currently non-treated cases were treated (sometime) before  (such is an 
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 CURRENTLY PROGRESSIVE (N=98)  
 
Under DMT (May 2014) 
N= 58 (59,2%) 
No DMT (May 2014) 
N=40 (40,8%) 
p 
Age at diagnosis (years-
old) 
39,5 (±12) 43,3 (±10,1) n.s 
Disease evolution time 
(years) 
12,2 (±8,3) 12,4 (±7,9) n.s. 
Current Age (years-old) 51,8 (±11,0) 55,8 (±9,5) n.s. 
% Females 70,7% 62,5% n.s. 
EDSS (median) 6.5 6.0 n.s. 
No DMT = Patient’s 
decision 
Not applicable 10,8% - 
Were previously on 
(other) DMT 
65% 55% n.s. 
Table 28. Comparison of the main characteristics of patients currently in progressive forms that were under disease 
modifying treatment (DMT) versus those not under DMT (in May 2014). 
 
When we analyze de proportion of treated patients by categories of EDSS, we see that all 
patients with RRMS forms are highly treated (around 90% cases)(Table 29). We’d previously 
seen that those not treated are above all very recent diagnosis, very long evolution time or 
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EDSS category N On DMT 
ALL PATIENTS 
<= 4.0 404 88,9% 
4.5-6.0 95 76,8% 
>=6.5 62 67,7% 
CURRENTLY IN RRMS 
<= 4.0 388 90,5% 
4.5-6.0 57 89,5% 
>=6.5 14 92,9% 
CURRENTLY IN PROGRESSIVE FORMS 
<= 4.0 13 53,8% 
4.5-6.0 37 59,5% 
>=6.5 48 60,4% 
Table 29. Proportion of patients on DMT in each EDSS category for each clinical type of disease. 
 
The proportion of our total population (progressive patients included) in each type of treatment 
is shown in Figure 34 (not excluding patients not under DMT) and Figure 35 (after excluding 
patients that where not on DMT in May 2014). 74,9% (approximately) of our treated patients 
were under first line DMT (interferons and GA), 21,3% were under 2nd line DMT (natalizumab 
or fingolimod), (around) 3,7% were on “other therapies” (these are explained under, for each 
clinical type).  
 
  
Figure 34. Distribution of types of DMT in our total population, not excluding those not on DMT. 
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From the total population classified as RRMS at diagnosis (n=508), then excluding those cases 
that were diagnosed as “RRMS already on SP” at diagnosis, we observe that 88,4% were under 
treatment in May 2014, independently of having reached SPMS in the meanwhile (which actually 
happened in 9,4% of these patients). 90,4% (n=415) of RRMS patients that were considered not 
to have reached SP phase (n=459), that’s to say of patients “currently in RRMS”, were under 
DMT in May 2014. The distribution of their treatments is shown in Figure 36and Figure 37. 
Interferons and GA together (first line therapies) totalize 76,6% of cases, Natalizumab and 
Fingolimod togeteher (2nd line therapies) totalize 21,5% of cases. “Other therapies” in Figure 37 
include mycophenolate mofetil, azathioprine and human immunoglobulin.   
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Figure 37. Distribution of types of DMT in our population of currently in RRMS that is on DMT. 
 
In total there were 53 patients with SPMS by inclusion: 38 were in RRMS at diagnosis, 5 were 
already in SPMS by diagnosis (Figure 38). Considering all patients in SPMS under DMT (Erro! A 
origem da referência não foi encontrada.), interferons and GA together complete 63.2% of 
cases, Natalizumab and Fingolimod together complete 26.3%, “other therapies” include 
ocrelizumab, mycophenolate mofetil and azathioprine. 
 
  
Figure 38. Distribution of treatments in SPMS population who were on RR phase by time of diagnosis (n=48). 
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Figure 39. Distribution of treatments of all patients in SPMS at inclusion on our study and on DMT in May 2014 
(patients not on DMT excluded). 
 
 
Figure 40 and Figure 41 show the distribution of DMT in the PPMS population. The 6 patients 









Paulo Alegria  Master’s Dissertation  2015  Page 60 
Faculdade de Ciências Médicas, Universidade Nova de Lisboa  College of Professional Studies, Northeastern University 
 
  




Level of education 
 
The mean number of years at school of the total population is 12±4,5 years (P25: 9; P75: 16 
years; min: 0; max: 27 years). If we only analyze patients older than 20 or 30 year-old, in an effort 
to exclude those cases that could still have their education incomplete by time of analysis, the 
result is about the same (in part this is due to the fact that we have only eight patients 20 years-
old or younger and 102 patients 30 years-old or younger, but this could also mean that by time 
of diagnosis the overwhelming majority of patients have their education complete or interrupt 
it). 
There is no difference between male and female patients (Figure 42). 
 
 
Figure 42. Number of years of school per gender, total population 
of our database. 
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There is a weak, although significant, correlation between year of birth (or age) and years of 
education (r=0,34, p<0,001, Pearson correlation), with older patients showing lower levels of 
education. If we only analyze patients older than 20 or 30 year-old in an effort to exclude those 
cases that could still have their education incomplete by time of analysis, the result is about the 
same (reasons pointed out above). 
Similarly, patients diagnosed more recently have generally higher levels of education (weak 
correlation) (Erro! A origem da referência não foi encontrada.).  
  
Figure 43. Mean years at school per year of birth of patients (left) and per year in time at which diagnosis 
occurred (right).  
 
Globally, if we look to the relation between age at diagnosis and number of years at school, 
there is no apparent relationship. It would be interesting to look only at diagnoses occurring 
before age 20 (then excluding cases that less probably would still have their of education on 
course by the time they were diagnosed with MS) for patients that have now 20 years-old or 
older (to assure those patients have had enough time to accomplish their complete education), 
but we have very few patients in that situation (Figure 44).  
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Figure 44. Mean number of years at school that patients that 
were diagnosed at each specific age accomplished. 
 
The number of total years at school is different in our populations of RRMS and PPMS (Figure 
45). As we showed before, these populations have different ages at present time: PPMS were 
born a longer time ago. External social factors not related to MS could then interfere with this 




Figure 45. Number of total years at school is different in RRMS 
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Economic activity and status of employment 
 
Considering the week immediately before inclusion, and according to ICSE-93, 61,5% (n= 345) of 
our total sample is classified as “economically active population” (Figure 46). 86,51% of these 




Figure 46.  Distribution of our total population in 




Figure 47.  Distribution of our total economically active 
population in terms of employment / unemployment. 
 
 
In Table 30we show the proportion of economically active and the unemployment rate for all 
our sample and for the group “RRMS at inclusion”. Data is shown for a selection of categories of 
gender, EDSS and age in each group. The difference in constitution between these 2 groups is 
essentially the presence of SPMS and PPMS in the whole sample.  
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Older patients, patients with higher EDSS and women show a smaller proportion of economic 
activity.  
Patients currently in RRMS have also a higher proportion of economically active than the whole 
sample (which, as stated, includes progressive forms). We had seen before that progressive 
forms are older at inclusion and have higher EDSS than patients in group RRMS at “inclusion”.  
This difference in the proportion of economically active patients between the 2 groups is, 
though, apparent even inside the same age category. This could be related with higher EDSS of 
patients in progressive forms even inside the same age category.  
Rates of unemployment seem higher in women, higher EDSS and higher ages, all classes that 
already have less economic activity.  
 
 








All 561 61,5% 13,5% 459 71% 12,7% 
All males 164 68,9% 8,9% 131(*) 80,2% 9,3% 
All females 397 58,4% 15,7% 328(*) 67,4% 15,7% 
All EDSS <= 
4.0 
404 74,3% 12,5% 388 75,5% 12,4% 
All EDSS 
4.5-6.0 
95 34,7% 12,1% 57 45,6% 11,5% 
All EDSS 
>=6.5 
62 19,4% 45,5% 14 50% 33,3% 
Current 
Age 20-29 
85 82,4% 20,3% 83 83,1% 19,1% 
Current 
Age 30-39 
164 85,4% 14,4% 150 88,7% 13,6% 
Current 
Age 40-49 
131 68,7% 9,0% 113 74,3% 8,4% 
Current 
Age 50-59 
111 31,5% 5,7% 73 41,1% 3,3% 
Current 
Age 60-69 
55 16,4% 22,2% 30 30% 22,2% 
(*) RRMS at inclusion females: age 41,2±12,1 years-old, median EDSS 2.0; RRMS at inclusion 
males: age 39,2±10,1 years-old, median EDSS 2.0. 
Table 30. Proportion of economically active and the unemployment rate (in the week before inclusion) for selected 
categories of our sample and for RRMS at inclusion.  
 
 
InTable 31we show the same data for patients SPMS at inclusion and PPMS (with or without 
relapses). 
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All 53 17% 44,4% 45 17,8% 12,1% 
All males 13 23,1% 0% 19 26,3% 0% 
All females 40 15% 66,7% 26 11,5% 33,3% 
All EDSS <= 
4.0 
1 - - 12 41,7% 20% 
All EDSS 
4.5-6.0 
22 18,2% 25% 15 20% 0% 
All EDSS 
>=6.5 
30 16,7% 60% 18 0% - 
Current 
Age 20-29 
1 - - 1 - - 
Current 
Age 30-39 
5 60% 33,3% 7 28,6% 50% 
Current 
Age 40-49 
11 27,3% 33,3% 7 42,9% 0% 
Current 
Age 50-59 
20 10% 50% 17 17,6% 0% 
Current 
Age 60-69 
14 0% - 11 0% - 
In view of the low number of patients in many categories, this table should only be 
interpreted as a general perspective on the subject. 
Table 31. Rates of economic activity and uenmployment in SPMS and PPMS patients. 
 
In Table 32 we compare the main characteristics of Active and Non-Active populations. As 
already suggested in the previous tables, non-actives are older (but mean age is only 50 years-
old), more frequently females, have more progressive forms (less RRMS at diagnosis) and higher 
EDSS. They are also less educated. The comparison of EDSS (in May 2014) between economically 












Paulo Alegria  Master’s Dissertation  2015  Page 66 








N 345 216 - 




Whitney U test) 














Whitney U test) 
Median EDSS (May 
2014) 
1,5  
(P25: 1,0; P75: 3,0) 
5,0  
(P25: 3,0; P75: 6,0) 
p<0,001 (after 





Table 32. Comparison of the main characteristics of Active and Non-Active populations. 
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Figure 48. Comparison of EDSS (in May 2014) between 




In Table 33 we compare the main characteristics of Active and Non-Active RRMS at inclusion 
patients. Non active RRMS patients are older, they are more frequently female, they are less 
educated and they have higher EDSS than their economically active counterparts. More than 









N 326 134 - 




Whitney U test) 





Years of education 
(mean) 




Whitney U test) 










Table 33. Comparison of the main characteristics of Active and Non-Active currently RRMS populations. 
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In Erro! A origem da referência não foi encontrada. it is apparent that unemployed patients are 
slightly older and are more frequently females but this doesn’t attain statistical significance. 
Education and type of MS don’t differ. Unemployed have a slightly higher EDSS. Our data shows, 
then, explanations for the fact patients are in the economically active or non-active groups, but, 
once inside the economically active group, the explanation for the distribution between 
employed and unemployed seems to be other factors that are not comprised in our dataset.  
 




N 295 46 - 
Age at inclusion 38,7±9,2 years-old 35,5±9,3 
n.s. (Independent-
samples Mann-
Whitney U test) 
% of females 65,4% 78,3% 
n.s. (Pearson Chi-
Square test, Cochran 
criteria verified) 
Years of education 13,53±3,7 13,63±2,7 
n.s. (Independent-
samples Mann-
Whitney U test) 
% of RRMS 95,9% 89,1%  
Median EDSS (May 
2014) 
(Erro! A origem da 
referência não foi 
encontrada.) 
1,5  
(P25: 1,0; P75: 3,0) 
2,75  
(P25: 1,0; P75: 4,0) 
p=0,008 (after 





Table 34. Comparison of employed vs unemployed populations (both part of the active population). 
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In Table 35 we present the comparison between employed RRMS patients and unemployed 
RRMS ones. It is not very different from the comparison between employed and unemployed in 
the global sample because there is only a small part of progressive patients that belong to the 
economically active group. Here younger age seems associated with more unemployment 
(unemployment of younger people is a phenomenon known in Portuguese society in actuality.) 
 
 RRMS employed RRMS unemployed p 
N 281 41 - 













Years of education 
(mean) 






Median EDSS 1.5 2.0 n.s. 
Table 35. Comparison between employed RRMS patients and unemployed RRMS ones. 
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98,2% of all the employed patients in our sample said they had only one job, 1,8% had various 
jobs.  
For the main job, the status of employment is represented in fig xxx. 81,6% are “employees”, 
only 3,4% are employers.  
The type of contract (the bond) with the main job is shown in fig xx. 80% have a regular contract 
with no term.  
Employed patients reported 40,13±10,9 hours of work per week.  
We also asked patients if their disease interfered with their ability to work: 69% said no, 31% 
said yes.  
 
The type of unemployment: voluntary in 29,8%, involuntary in 70,2%. 
95% of unemployed had an employment before.  
52% of unemployed think MS is not the main cause of their unemployment; 26,1% say it’s the 




Figure 50. Distribution of the employed population in terms of the employment status (for their main 




Paulo Alegria  Master’s Dissertation  2015  Page 71 








Non-active population constitutes 38,5% (n= 216) of our total cases. Stratifying these patients 
by their economic situation shows that the great majority (74,1%) have a retirement due to 




Figure 52. Distribution of all Non-Active population by subtypes of 
economic situation.  
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RRMS at inclusion economically non-active: 69,5% retired due to disease, 13,7% student, 11,5% 





Of 397 women in our database, we have data on gestations and live births, before and after the 
diagnosis of MS, for 394 (99%). Mean age at diagnosis of women in our database was 34±11,5 
years-old. 15,0% had live births after the diagnosis of MS. 
When we compare only the population of women whose diagnosis occurred during the years 
1991 to 2000 versus those whose diagnosis occurred during the decade 2001-2010 (we have low 
numbers before 1990 and diagnosis after 2009 are also still few and they have a short follow 
up), the percentage of women that had live births is, correspondingly, 15% and 19% (n.s., 
Pearson Chi-Square test).  So, even considering the fact that this late group has a shorter follow-
up (some of these patients could still become pregnant) and that births in Portugal have been 
decreasing (according the Portuguese National Statistical Institute - INE), the proportion of 
women becoming pregnant after the diagnosis of MS, increased (Table 36).  
 
 
Table 36. Percentage of women with and without live births after 
diagnosis per decade in time at diagnosis. 
 
 
When we only consider the women whose diagnosis occurred before 35 years-old (then 
excluding a part of the population less prone to become pregnant), this difference is even larger: 
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23,8% of females whose diagnosis occurred in the decade of 1991 to 2000 and that were under 
35 years-old at the time of diagnosis (n= 42) had live births till the date of CRF filling whereas 
this same number for the corresponding diagnosis occurring in the years 2001-2010 (n=108)  is 









N 70 173  
Age at 1st symptoms 30,76±11,0 31,1±10,8  




18,0±2,8 9,1±3,0  
Age at inclusion 52,81±11,0 43,2±11,3  
RR at diagnosis  91,4% 94,8%  
RR at diagnosis that 
progressed to SP at 
inclusion 
23,4% 9,8%  
EDSS (May 2014) 
4,0 (n=58 data 
available 
2,0 (n=139)  
Level of education 
(years) 




(data for n=46) 
61,9% 
(data for n=118) 
 
Mean number of 




(data for n=46) 
1,6 
(data for n=118) 
 
Had live births 
before diagnosis 
63% 
(data for n=46) 
57,6% 
(data for n=118) 
 
Mean number of live 
births (for those 
1,7 
(data for n=46) 
1,5 
(data for n=118) 
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Had gestations after 
diagnosis 
17,1% 
(data for all 70) 
23,1% 
(data for n=169) 
 
…of which had been 
pregnant before 
   
Mean number of 




(data for all 70) 
1,3 
(data for n=169) 
 
Had live births after 
diagnosis 
17,1% 
(data for all 70) 
18,3% 
(data for n=169) 
 
Mean number of live 




(data for all 70) 
1,1 






7,8% (43 patients out of 553 with data available) of our population reported to have some blood-
related family with a confirmed diagnosis of MS (Erro! A origem da referência não foi 
encontrada.). Even if we, arbitrarily, select a subgroup of older MS patients by the time of CRF 
filling, these percentage remains relatively stable (mean age at diagnosis of cases with positive 





 Frequency Percent Valid Percent 
Valid irmão/irmã 6 1,1 1,1 
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filho/filha 4 ,7 ,7 
pai/mãe 8 1,4 1,4 
tio/tia em primeiro grau 
materno ou paterno 
4 ,7 ,7 
primo(a) direito(a) 
materno ou paterno 
12 2,1 2,2 
outro 6 1,1 1,1 
varios 3 ,5 ,5 
NENHUM 510 90,9 92,2 
Total 553 98,6 100,0 
Missing  8 1,4  
Total 561 100,0  
 
Table 37. Distribution of patients with positive family history by relative degree. 
 
 
The proportion of positive family history in male and female patients is similar (8,7%  vs. 7,4%, 
respectively).  
The proportion of PPMS patients (with or without relapses) with positive family history is not 
different from the corresponding value within RRMS patients (6,7% of 45 patients vs. 7,9% of 
513, respectively).  
Although we found a bigger proportion of patients with positive family history for those with a 
diagnosis in the decade of 1991-2000 (11% of 118 patients) than for those with a diagnosis 
during the decade of 2001-2010 (6,7% of 268 patients), we are unsure about the significance of 
this and we will confirm this data when we will have a bigger number of patients (for other 





We currently have very little variability in race/ethic origin in our database, for which an analysis 
is deferred.  
Issues related with migrations will be analyzed posteriorly, as will data on the place of residency 
at birth, place of residency at first symptoms and place of residency at diagnosis. Some of these 
analyses will need confrontation with general epidemiological national data.  
For what concerns data on participation in clinical trials we detected an error on the 
interpretation on the question after perceiving, in our data, an unexpected high number of 
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patients reported to have participated in clinical trials (compared to what is the common notion 
of neurologists working in the field in Portugal). Some investigators had accepted fase IV trials 
and other observational studies without intervention as iterventional clinical trials. We are 
considering to review the data of all patients on this matter. 
Other data on pregnancy and miscarriages, other data on level of education and status of 
employment, data on BMI, attribution of the legal status of physical/mental incapacity and need 
for a caregiver (and other data), are waiting for analysis. 
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Discussion 
Our study is the first multicentric national wide study to provide epidemiological and clinical 
data on MS patients in Portugal. Considering the estimated prevalence of MS in Portugal, 
patients included in this pilot PORT-MS study represent approximately 10% of all MS patients in 
our country.  
Our study has, of course, various limitations. The main ones are: 
- Cross-sectional and retrospective collection of data, with many possible recall bias. To 
diminish this limitation we used every source of information we could (the patients’ file 
and direct interviews with the patient himself and the treating neurologist); 
- Use of a hospital-based instead of community-based source. A selection bias can be 
present. In these 7 big dimension hospitals there could be a tendency to over represent 
more severe cases or cases being treated with more 2nd line drugs. On the other hand, 
although we performed sequential recruitment in all areas of the hospital where we 
could find these patients, we know that the most disabled or institutionalized patients, 
some of them having stopped the use of DMT, don’t come to the hospital so frequently. 
Some of these bias could be overcome by the recruitment of all the population of MS 
patients in each hospital, which is one of our objectives. 
- We still have a globally small number of patients and a superior number of MS centers 
has to be integrated. In certain clinical groups (such as PPMS), or in some ethnic groups, 
we have relatively few patients, which limits the analysis of clinical characteristics of 
these patients. 
- We detected an erroneous interpretation of the questions regarding the participation 
of patients in clinical trials, as stated in the results section, and we will have to correct 
that. 
Our study has, has on the other hand, comparing to other European registries on MS patients, 
superior range of details in some aspects, namely regarding the educational level, the status of 
employment or the obstetric data in MS female patients (Fig 46 shows a summary of the PORT-
MS pilot study results). Our objective was not to be exhaustive, though. We aimed at a general, 
well performed, portrait of the Portuguese MS population, and, above all, we avoided a too 
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General demographics and disease milestones 
Our data are generally similar to those obtained from other countries’ MS registries. Regarding 
the average age of the patients, the disease duration, the age at onset and the transition from 
the onset of the illness to the diagnosis, we found closer similarity to the German MS registry 
(44.2±11.5 years; 12.7 ± 9.2 years; 31.4 ± 10.2 years; 3.4 ± 5 years, respectively – data from the 
two-year pilot study) (Flachenecker 2008). This makes us believe, despite the limitations stated 
above, that our sample may be representative of the population of interest.  
When we analysed the age of onset (firs symptoms) and age at diagnosis in each decade in time, 
we found a slight increase in more recent times. This contrasts with the significant decreasing 
observed in the National Swedish MS Register (Boström 2012). We have currently no definitive 
explanation to this fact, it will have to be confirmed with a larger number of patients. One 
theoretical explanation could be the more accurate diagnosis of progressive patients in more 
recent times. We registered, on the contrary, a the tendency to decrease in the time from first 
symptoms to diagnosis more recently, which is also reported in other registries, and in 
agreement with the effect expected from better diagnostic methods available nowadays.   
The significant higher age of onset when we compare the PP with the RR forms in our study is 
according to the literature (McDowell 2010).  
The female to male ratio of our sample fits the interval found by Pugliatti in his review article 
about the women-to-men ratio for MS in Europe (1.1-3.4) (Pugliatti 2006). Several studies (in 
Canada, New Zealand, Denmark, Sweden, among others) have demonstrated an increased 
women-to-men ratio in MS throughout decades, presumably due to an increased incidence in 
women rather than a decline in men (Orton 2006, Trojano 2012, Koch-Henriksen 2011, Boström 
2012). However, the proportion of male to female seems globally stable in our study, when 
analyzing by date of birth or by decade in time at which the diagnosis was made. Similar to the 
Norwegian MS Registry (Kampman 2013), in our study the overall sex ratio of MS is strongly 
determined by cases with RR onset, as in our PP patients, women and men are almost equally 
affected (1.1:1).  
 
Clinical course 
The distribution of prevalent cases by disease course is a hard task. Some disease subgroups are 
not considered in some reports (like PPMS with relapses, which is equivalent to PRMS). Other 
times, classically distinguished groups like PPMS and SPMS are treated as one group. 
Additionally, in some articles, these two last categories are sometimes omitted.  
RRMS ranged from 24% (The Netherlands) to 88% (Greece) of prevalent cases. In PORT-MS it is 
82%.  
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In our study, only 10,8% (60/558) have combined RPMS+SPMS. As we can see in the Figure 53, 
whereas combined proportion of RPMS and SPMS ranged from 4% (Sweden) to 50% (Bulgaria), 
in PORT-MS that value is relatively low. There is a substantial discrepancy between PORT-MS 
and the results of the extension phase 2005/2006 of a German study, with a much higher 
number of combined SPMS+RPMS cases in the Germany study: 10,8% vs. 32%, respectively. The 
survey was not population-based, relying instead on specific data provided by study centers, 
which may have led to selection bias (Flachenecker 2008). 
 
Frequency of PPMS (without relapses) was 6,9% in PORT-MS, which is in the lower end of the 
range from 4% (Austria) to 35% (The Netherlands) (Pugliatti 2006). Subjectively the authors 
believe that PPMS patients (which no longer do DMT, are older and very disabled patients) come 
less frequently to the outpatient clinic, if at all, which may bias our sample even if the 
recruitment is strictly sequential. This may, at least partially, justify our low proportion of 
progressive forms of MS.  
Regarding the initial MS type, our results are comparable to a recent study in the Spanish 
population (based on EDMUS), in which the clinical course was RRMS in 93.3% of the patients 
(PORT-MS 91,4%) and PP in the other 6.7% (in PORT-MS 8,6% of patients started with PPMS, 
with or without superimposed relapses) (Romero-Pinel 2010).  
The difference in proportion of RRMS and SPMS between PORT-MS and studies prior to the date 
of 1993 (approval of the first DMT) may eventually reflect some effect of therapies (although 
that effect has been difficult to prove in the long-term course of this disease) (Derwenskus 
2011). In studies after 1993, differences between the countries could also be related with 
different availability of DMT (the advent of DMT probably changed the population that more 
frequently come to clinics).  
In PORT-MS study, the percentage of patients that progressed to SPMS at 10 years of evolution 
was 3,3% and at 15 years 5%. These values are lower than those of a Germany study of 2006 for 
example, where after approximately 10 to 15 years, 30% to 40% of patients with initial RRMS 
enter the SPMS. It shows that the patients included in our study have less SPMS diagnosis and 
this could be probably due to selection or recall bias, with misinterpretation of retrospective 
data from patients (Flachenecker 2006). 
As stated above, from those patients initially diagnosed with RRMS, the mean age for patients 
not progressing to SPMS is 41 years-old at present time, whereas those that evolved to SPMS is 
55 years-old. The shorter the disease duration, the fewer the cases with SPMS within the 
population of cases having an initial RR course. 
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In the extension phase 2005/2006 of the Germany nationwide MS registry, the median EDSS 
score was 3.5 (PORT-MS - Median EDSS for the 465 patients with exact EDSS available is 2,5) 
(Flachenecker 2008). In a Portuguese study about the prevalence of MS in the District of 
Santarém (n=29) the mean EDSS was 3,2 (De Sá 2006). 
In total, 51% of patients were fully ambulatory (EDSS < 4) (PORT-MS – EDSS ≤ 4 – 72,7%), 28% of 
patients required assistance (cane, crutch, brace) to walk 100 m (EDSS ≥6 and < 8) (PORT-MS – 
18,0%), and 6% were confined permanently to a wheelchair (EDSS≥8) (PORT-MS – 1,1%) 
(Flachenecker 2008). 
Analysing patients in PORT-MS database for whom we have exact EDSS, we ascertain, for the 
RRMS group (n= 420), a median EDSS of 2,0 and for PPMS patients a median EDSS of 6,0. A British 



















































































































































































































































































































































































































































Prevalence of MS cases by disease type at the time of each study
RR RP+SP PP
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84.5% of all patients and 44.4% of PPMS patients were under DMT in May 2014. In a German 
study 71% of patients received immunomodulatory treatment, 20% of the PPMS population did 
receive immunoprophylactic treatment (Flachenecker 2008). 
If we include only the patients on Interferon, Glatiramer Acetate, Natalizumab and Fingolimod, 
the proportion of use by type of treatment is shown on Figure 54.  22% of our patients were 
under second-line immunomodulatory treatment (Natalizumab/Fingolimod). Higher values 
were ported in Australia 2013 (33%) and USA 2010-2011 (32%) (Hollingworth 2014, Bergvall 
2014, Windt 2013). 
37% of PPMS and 70.8% of SPMS patients were under DMT in May 2014 - for the year 2009, 
outpatient setting, German Bavaria population, the values for PPMS and SPMS were significantly 
lower (20% and 59%, respectively) (Hoer 2014). Also for another German study concerning the 













PORT-MS, 2014 (n=456) 22% 37% 19% 12% 10% 
Australia, 2013 11% 44% 12% 12% 21% 
USA, 2010-2011 (n=3.750) 36% 33% 8% 24% 
Figure 54. Proportion of the different DMT used in MS in various studies. 
 
 
Education and status of employment 
Concerning this subject, the current national MS registries available worldwide do not include 
the educational level nor the employment status on their published data (Cristiano 2009, Otero 
2010, Hurwitz 2010, Ahlgren 2011, Koch-Henriksen, Brønnum-Hansen 2011).  
Our study shows that, on average, the Portuguese MS patients possess a higher educational 
level compared to the general Portuguese population and the correlation demonstrated 
between the year of diagnosis and the educational level may be interpreted from the point of 
view of social and economic changes that the country has suffered in the last decades. 
Other studies have previously shown the relevance of sustaining employment after the diagnosis 
of MS, in particular, concerning health-related quality of life (Patti 2007, Van der Hiele 2014). 
The rate of unemployment in PORT-MS patients is 13,5% (comparable with the 13,9% Portugal 
unemployment rate in the second quarter of 2014 reported by the Statistics Portugal).  However, 
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the overall rate of unemployment in the MS population has a marked range and its value can 
reach 80%. This variation may be due to factors related to the country, differences in patients, 
disease and work-related characteristics as well as the definition of employment used 
(Shahrbanian 2013). 
Our data concerning the employment status in the previous week show a higher percentage of 
economically active population compared to several countries namely Netherlands, Norway and 
United Kingdom (Van der Hiele 2014, Lunde 2014, Jones 2013). 
Employed patients had a median EDSS of 1,5 and unemployed a median of 2,75. Data of a sample 
of patients attending an MS outpatient clinic in UK showed values of EDSS of 5,7 and 6,8 
respectively (O'Connor 2005). So, as previously shown in several other studies, we demonstrate 
that lower levels of neurological disability are associated with employment status (Van der Hiele 
2014, Lunde 2014).  
PORT-MS showed that the great majority of non-active MS patients (74,1%) have a disability 
pension, which is consistent with data from previous studies (Lunde 2014, Cores 2014). Another 
study based on data from 9,721 MS patients in Sweden during 2005 also showed high prevalence 
of disability pension among MS patients (61,7%) compared to 14.2% among the controls 
(Tinghög 2013). 
We may recognize as a limitation of our study the fact that we did not search for other factors 
contributing to unemployment or early retirement, namely the co-occurrence of other diseases 
such as depression and certain MS symptoms such as fatigue and cognitive impairment. 
 
Pregnancy 
During the first half of the 20th century, female MS patients were often discouraged from 
becoming pregnant (Borisow 2014). It is now known that fertility is not affected in MS, that the 
risk of relapse declines during pregnancy and that the course of pregnancy and obstetrical 
outcomes are similar to those of women without MS (Hellwig 2014). Our results suggest that, 
although in Europe and Portugal the number of live births is currently declining, the proportion 
of MS female patients giving birth to live children is increasing. We can speculate that the wider 
knowledge of the disease and the largest range of treatments available at present explain this 
reduced uncertainty on the part of women with MS to get pregnant. Concerning this subject, 
data are scarce in the existent national registries (Cristiano 2009, Otero 2010, Hurwitz 2010, 
Ahlgren 2011, Koch-Henriksen 2011, Brønnum-Hansen 2011) and there are only a few small 
studies approaching pregnancy prevalence in MS patients (Andersen 2013). 
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Familial MS 
Our prevalence of familial MS of 7.8% is slightly lower than the generally accepted in the 
literature (Farez 2014, Hader 2014), although there are few studies, namely Spanish ones, with 
similar prevalence (Iglesias 2014, Viswanathan 2013). 
Concerning family history, we did not enquire about the dimension of families, ease of access to 
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General epidemiological or demographic are not different from what has been described in 
other European or North American studies, notably in what concerns the age at first symptoms 
and diagnosis and the proportion of females to males. The time from first symptoms to diagnosis 
has decreased recently. This gives us the idea that patients are correctly identified and followed-
up. PPMS takes more time to be diagnosed than RRMS. 
 
Globally there is a big proportion of patients under DMT in Portugal, including in high EDSS and 
progressive forms. Second line therapies are underrepresented. This gives us the idea that 
Portuguese doctors are willing to treat this patients but somehow they use less frequently more 
recent or more efficacious (and more risky?) therapies. 
 
Mildly incapacitated patients have rates of activity and employment similar to general 
population; these are much reduced in relatively young patients with moderate and high 
incapacity, essentially due to retirement due to disease. This  
 
In Table 38 the main results of PORT-MS study are shown. 
 
Result Value Additional data 
Total number of patients 
in PORT-MS 
561 
Estimated to correspond to 10% of the 
Portuguese patients with MS 
Race / ethnicity 98,9% white  
Place of birth 92,9% in Portugal  
Nationality 94,3% Portuguese  
Gender proportion 2,5♀: 1 ♂ 
2,5♀: 1 ♂in RRMS, 1,1♀: 1 ♂ in PPMS,  
p<0,05.  
Gender proportion has been stable 
throughout the last decades and at 
different ages at diagnosis. 
Age at first symptoms 30,2±10,5 years-old 
29,2±10 for RRMS, 39,4±11,7 for PPMS, 
p<0,001. It has slightly increased in the 
last decades (p=0,009). 
Time from first symptoms 
to diagnosis  
3,2±5,3 years  
3,0±5,1 in RRMS, 4,9±2,5 in PPMS, 
p=0,002. Stable in the last few decades, 
apparent decrease in the last few years. 
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Age at diagnosis 33,4±11,1 years-old 
32,3±10,4 in RRMS, 44,2±11,6 in PPMS, 
p<0,001 It has  slightly increased over the 
last few decades (p=0,035). 
RR versus PP at onset and 
at diagnosis 
91,9% started with RR type of 
disease (although some were already 
in SP at diagnosis), 8,1% with PPMS, 
with or without relapses. 
This proportion has been stable 
throughout the last few decades. Patients 
diagnosed later in life show a higher 
proportion of PPMS (p<0,001). 
Years of evolution after 
diagnosis 
9,4±7,2 years 
no difference between RR at diagnosis and 
PPMS at diagnosis 
Age at present time 42,9±12,4 years-old 
42,0±12,1 for RRMS at diagnosis, 
52,5±11,3 for PPMS at diagnosis, p<0,001 
% of patient initially 
diagnosed in RRMS phase 
that evolved to SPMS 
9,5% 
Patients that reached SPMS have more 
time of evolution of disease and are older. 
This value is: 2,3% at 5 years after 
diagnosis, 3% at 7 years, 3,3% at 10 years, 
5% at 15 years, 6,6% at 20 years. 
Median EDSS at present 
time 
2,5 2,0 for currently RRMS, 6,0 for PPMS. 
Proportion of total 
patients on DMT 
84,5% 
90,4% of currently in RRMS; 88,4% of 
RRMS at diagnosis; 71,6% of all currently 
SPMS; 59,2& of all progressive forms 
together; 44,4% specifically in PPMS. 
Mean number of years at 
school of the total 
population 
12±4,5 years 
Equal for male and female. Younger 
patients have higher levels of education. 
Economically active versus 
non active population 
61,5% active, 38,5% non-active.  
Unemployment rate 13,5%  
Retirement due to disease 74,1% of non-active population  
Women that became 
pregnant after diagnosis 
of MS 
15%  
Proportion of cases with 
positive family history 
7,8%  
Table 38.  Summary table of the main PORT-MS study results. 
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Summary of contributions 
 
The main contributions of this work for the resolution of the problems stated in the introduction 
of this dissertation are: 
- The successful development of collaborative multicentric work between different 
hospitals and different regions of our country, notably in the field of MS, which, 
historically, has not been frequent; 
- The production of the first national data on the characteristics of M, of MS patients and 
of MS care, even if for now including only 10% of the national population of MS; 
- To foster a national registry of this disease, similar to what happens in the majority of 
the developed countries. 
 
See Table 38, where the main data we produced is presented.  
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After November 2014, a “phase 2” of this study started, during which the PORT-MS study aims, 
during the next 1-2 years, to include the totality of patients of each center and involve additional 
centers in Portugal. 
The development of the PORT-MS registry is also in my plans, as in the plans of the other co-
authors, co-investigators and of Portuguese MS neurologist in general. My idea would be to start 
with an update of a selected group of data every May. I’m personally designing PORT-MS 2015 
/ PORT-MS registry. 
Ideally we intend to create a PORT-MS web-system available for every neurologist in the country 
who treats patients with MS and wishes to include his patients in the database.  
Such a registry could be used as a tool to other studies, providing samples of patients for clinical 
research, case-control studies and prospective studies.  
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Complete study protocol 
 
In the following pages I present the complete study protocol as it was submitted to study 
centers, ethics committees and CNPD (the National Committee for data protection). I was the 
author of this protocol and the national coordinator of the study, although many colleagues 
reviewed it with me. The global document is originally in English language, although a 
Portuguese version was created to submission to the CNPD exclusively. The CRF and the 




CLINICAL STUDY PROTOCOL 
 




Title: PORT-MS (PORTuguese database of Multiple Sclerosis) – A national survey to 
describe current demographic and clinical characteristics of patients with Multiple 
Sclerosis in Portugal 
 
Study code: PORT-MS 
 
Type of study: Observational 
 
Date of protocol: 27/Mar/2014 
 
Version no.: 3 
 
Name of Coordinating 
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independent ethics committee or regulatory agencies.  
The information in this document cannot be used for any purpose other than the evaluation or 
conduct of the clinical investigation without the prior written consent from the PORT-MS study group. 
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PRINCIPAL INVESTIGATOR SIGNATURE PAGE (to be signed by the PI from each 
participating center) 
 
Study Title: PORT-MS (PORTuguese database of Multiple Sclerosis) – A national survey to describe 
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amendments, and all applicable Health Authority requirements and national laws. 
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1. PROTOCOL SYNOPSIS 
 
Title:  PORT-MS (PORTuguese database of Multiple Sclerosis) – A national 
survey to describe current demographic and clinical characteristics of 
patients with Multiple Sclerosis in Portugal 
Study Code: PORT-MS 
Authors: Paulo Alegria1, João Ferreira2, João Sequeira3, José Tomás4, Miguel 
Grilo5, Raquel Samões6, Sara Varanda7, José Vale1, Maria José Sá5 
1 – Serviço de Neurologia, Hospital Beatriz Ângelo, Loures, Portugal ;  
2 – Serviço de Neurologia, Hospital de Santa Maria, Centro Hospitalar de 
Lisboa Norte, Lisboa, Portugal;  
3 – Serviço de Neurologia, Hospital de Santo António dos Capuchos, 
Centro Hospitalat de Lisboa Central, Lisboa, Portugal;  
4 – Serviço de Neurologia, Centro Hospitalar Universitário de Coimbra, 
Coimbra, Portugal;  
5 – Serviço de Neurologia, Centro Hospitalar de São João, Porto, Portugal;  
6 – Serviço de Neurologia, Hospital de Santo António, Centro Hospitalar 
do Porto, Porto, Portugal;  
7 -  Hospital de Braga, Braga, Portugal 
Study Phase (optional):  Not applicable 
Disease/Condition Multiple Sclerosis 
Rational 
 
In Portugal, demographic and epidemiological clinical data about Multiple 
Sclerosis at a regional or national level are scant. There is no national 
registry for this condition and never a simultaneous and systematic 
collection of data from the whole country has been performed for this 
disease. 
Neurologists who follow patients with MS in Portugal will be invited to 
collaborate in this study as investigators and recruit patients (after 
approval by competent institutions and informed consent) and collect data 
(hospital-based study) about basal demographic and clinical characteristic 
of their patients, referent to the month of May 2014. 
A first step of the study will run in the centers the authors of the study 
are connected to and recruit until August 2014. A second step will extend 
the study to the whole country and aim at the maximum number of 
patient possible.  
Primary Objective: To describe basal demographic and clinical characteristics (taking May 
2014 as the reference date) of the largest possible number of patients 
with the diagnosis of Multiple Sclerosis that are on medical follow-up by 
neurologists in Portugal. 
Secondary Objective(s): • To compare Portuguese data with previous national and international 
published data. 
• To analyze data of MS patients comparing them with data from the 
general population, as for instance in geographic patterns of place of birth 
and place of residency, education and labour.  
• To analyze the attractiveness of the country for the implementation of 
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future clinical trials considering the data collected and especially the 
number of patients naïve to trials. 
Exploratory Objective(s), if 
any: 
There are no other specific exploratory objectives besides what is stated 
above. 
Primary hypotheses (if 
applicable):  
There are no specific primary hypotheses. 
Study Design:  This is an observational, cross-sectional, descriptive, multicentric, national 
study. 
Inclusion Criteria: Patients alive and with the diagnosis of MS in any day of May 2014 
(Positive McDonald 2010 criteria for Multiple Sclerosis, including “no better 
explanation”). 
Informed consent. 
Exclusion Criteria: No positive McDonald 2010 criteria. This includes the exclusion of patients 
with an alternative clinical diagnosis more plausible than Multiple Sclerosis 
even if other aspects of McDonald 2010 are satisfied. 
No informed consent.   
Withdrawal criteria (if any) Patients that withdraw consent 
Patients for whom an alternative diagnosis was discovered after inclusion 
in this study 
Expected number of subjects: Based in previous estimates, the number of MS patients in Portugal is 
around 5000. The aim of this study is to recruit the maximum number of 
patients that is possible. For “step 1” of this study (see below) the 
expected number of subjects is around 500.  
Expected number of sites: All public and private hospitals and clinics that are known to have MS 
patients on follow-up and treatment by neurologists will be invited to 
integrate the study. The expected number of sites is around 50. 
Subject selection Neurologists will recruit patients directly from outpatient clinics (or, more 




Study Procedures: This is an observational cross-sectional study. After informed consent by 
the patient, data will be collected at a single time point from the patient’s 
file and from patient’s interview (to complete missing information). The 
participant’s contribution will then be finished and he won’t be subjected 
to any other intervention. 
Main data collected:  Main variables include: date of birth, place of birth, sex, ethnic origin, 
race, date of first symptoms, place of residency at first symptoms, date of 
diagnosis, place of residency at diagnosis, initial type of MS, date of start 
of secondary progressive MS, current treatment and date of start of that 
treatment, EDSS, employment status, previous participation in clinical 
trials. Please see CRF for details. 
Endpoints Not applicable. 
Statistical methods Variables will be described through descriptive statistics, namely absolute 
(n) and relative frequencies (%) for qualitative variables and mean, 
median, standard deviation (SD), minimum and maximum for quantitative 
variables. 
All patients with data at least in date of birth, sex and date of diagnosis 
will be considered, even if missing variables exist. Missing values will not 








Overall Study Duration: Three years, starting from first center approved around June 2014. 
Study timelines:  Estimated EC Approval - first center approved by June 2014. 
Recruitment is expected to occur between June 2014 and August 2014 for 
the first step of this study, until June 2015 for the second step.  
The Implementing/Scientific Committees may prolong recruitment for one 
year.  
Data analysis will be continual, for around 3 years starting from 
recruitment. 
 








2 INTRODUCTION  
2.1 CLINICAL BACKGROUND 
 
Clinical registries, surveys of regional and national level and epidemiological studies, whether 
cross-sectional or longitudinal, physician- or patient-driven, are useful to increase knowledge about a 
certain disease or condition in many ways, including in aspects related with the etiology, clinical 
characterization, diagnosis, treatment, demography and epidemiology of that condition. Even 
relatively simple registries or surveys can be of extreme importance for a correct (cost-effective and 
adapted) planning of healthcare resources allocation in a certain region or country.  
Beginning in the 5th and 6th decades of the previous century with several epidemiological studies, 
mainly focused on incidence and prevalence, now it’s widely recognized that multiple sclerosis (MS) is 
one of the neurological diseases with the best-documented epidemiological studies (1). Registries of 
patients with MS constitute important repositories of information on the long-term course of the 
disease and provide complementary and valuable data in parallel with clinical trials, namely related to 
a better understanding of risk factors, disease process and progression. One of its major strengths is 
the inclusion of a very large number of patients that would be difficult to recruit in other studies, 
overcoming some limitations of the power of many clinical trials. Registries in MS are best suited to 
provide information about the prevalence, current treatment patterns, and patients’ outcomes, and 
are particularly informative if multiple registries confirm the same findings. Some of the major 
criticisms, that have been pointed out to this type of observational study, are ascertainment bias due 
to incomplete registries and the huge commitment and effort that is required, so keeping a 
consistently collection of a minimum amount of information and obtaining the maximum possible 
ascertainment in a region or population are important factors to get high-quality information (2,3). 
Several registries have been established worldwide, especially in Canada, United States and Europe 
(3). The Danish Multiple Sclerosis Registry (DMSR) registry is one of the oldest in existence. This MS 
database is unique because it has existed for 60 years and covers a whole country with a high rate of 
ascertainment. DMSR is one fine example of how these observational studies have contributed to a 
better understanding of MS. For example, during the last 25 years, over 40 studies have been 
published based on this registry (4). 
In Portugal, demographic and epidemiological clinical data about Multiple Sclerosis at a regional or 
national level are scarce. A retrospective study was conducted in 1983 in order to estimate MS 
prevalence around Lisbon, based on the data of its main MS treatment centers. A prevalence of 
12.9/100000 was calculated (5,6). A population-based prospective study conducted over a period of 5 
years and published in 2006 revealed a prevalence of 46.3/100 000 in the district of Santarém (6,7). 
In 2010 a national transversal study using a survey determined a self-reported MS prevalence in 
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continental-Portugal, among adults of 54/100 000 and an estimated number of patients of 4287 
(varying between 2700 and 5875) (8). There is no national registry for this condition and never a 




The fundamental aim of this study is to gather efforts from an assembly of neurologists that follow MS 
patients in Portugal to constitute a study group that will produce a more complete (cross-sectional) 
national portrait of the population of patients with that disease in Portugal in 2014. This portrait will 
essentially focus on the verification of some demographic and clinical characteristics that are typical in 
MS (like age at diagnosis, preponderance of female gender, preponderance of certain ethnic, “race” 
and geographical origins (9), proportion of subtypes of MS and others) in an attempt to detect (or 
exclude) any  deviation in the Portuguese patients compared to the other European populations. A 
brief characterization of the current treatment will also permit a comparison of medical standards with 
other countries. A collection of data about education and labor, crossed with disease stage, will permit 
a comparison with the general population and eventually render some types of cost of this disease 
more clear in this country. Hopefully this study would also stimulate other studies that would focus on 
some points of interest detected in this first attempt of general characterization. The month of 
reference for the study will be May 2014. 
The actual planning of this study was born from a group of doctors that met in the context of a 
Pharma Industry (Biogen Idec Portugal) and GEEM (Grupo de Estudos de Esclerose Múltipla, the 
Portuguese national medical society for MS) – sponsored course of Multiple Sclerosis (“EMIN” 2nd 
edition) occurring during 2014.  
In a first step of this study, the mentioned group (the “Coordinating Committee” of this study) will use 
knowledge and resources of that course and work with the objective of implementing the study 
essentially in their centers and collect preliminary data until August 2014.  
Once accomplished that objective, collection of data continues in a second step aiming to recruit the 
maximum number of patients possible in Portugal, both by continuing recruitment in those original 
centers and by extending recruitment to other centers around the country.  
The Coordinating Committee will invite all neurologists who follow patients with MS in Portugal to 
integrate the study as investigators and recruit patients and introduce their data, if approved by theirs 
institutions’ superiors and ethics committees and consented by each patient (hospital-based study). As 
mentioned, only a nuclear group of centers is aimed at the first step of the study, neurologists from 
other centers will be invited subsequently. All neurologists that will contribute to the collection of data 
are investigators and authors and constitute the PORT-MS study group (please see study procedures 
section and authorship policy later in this protocol).  
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To help the Coordinating Committee analyzing data and publishing it (please see authorship policy 
later in this protocol), a Scientific Committee will be constituted amongst the main contributors to the 
PORT-MS data during 2015. This Scientific Committee will be composed by a representative of each of 
the 7 top recruiting centers.  
 
Of course, sponsors of the EMIN course, as other possible subsequent sponsors of financing, will have 
no access to data. Once the first step of this project and the EMIN course is completed, the project 
will run autonomously and without any commitment linked to EMIN.  
 
The Coordinating Committee functions are: 
- Conception of the study, diffusion, helping the practical implementation of the study in all centers, 
permanent contact with centers 
- Data assembly, data maintenance, data analysis, expectedly by working with other experts from 
PORT-MS study Group, and eventually with external experts (epidemiologists, statisticians and others)  
- Regular reports to the scientific committee about general progress of the study seeking advice in 
data analysis and publishing the results. The final list of authors for publications will be set up in 
accordance with the scientific committee (see authorship policy) 
- Seek financing and administration of finances (with reports to the scientific committee) 
- Report at least annually to all study investigators and preferentially more regularly by a mailed 
newsletter  
- Make available to every investigator a declaration stating that he/she is an investigator in the 
registry (eventually with the number of patients included) for him/her to use as he/she wishes.  
 
The Scientific Committee functions are: 
- Listen to the reports of the Implementing Committee and help analyze data and select the data to 
publish.  
- agree with the coordinanting committee a final list of authors for publications  
 
 








2.1 PRIMARY OBJECTIVE 
 
To describe basal demographic and clinical characteristics (taking May 2014 as the reference date) of 
the largest possible number of patients with the diagnosis of Multiple Sclerosis that are on medical 
follow-up by neurologists in Portugal. 
 
2.2 SECONDARY OBJECTIVES 
 
• To compare Portuguese data with previous national and international data. 
• To analyze data of MS patients comparing them with data from the general population, as for 
instance in geographic patterns of place of birth and place of residency, education and labour.  
• To analyze the attractiveness of the country for the implementation of future clinical trials 
considering the data collected. 
3 STUDY DESIGN 
 
This is an observational, cross-sectional, descriptive, multicentric, national study. 
4 STUDY TIMELINES 
 
Estimated EC Approval - first center approved by June 2014. 
Recruitment is expected to occur between June 2014 and June 2015.  
The Implementing/Scientific Committees may prolong recruitment for one extra year.  
Data analysis will be continual, for around 3 years starting from recruitment. 
5 STUDY POPULATION  
 
All the patients with the diagnosis of Multiple Sclerosis in May 2014 that are on follow-up by a 
Neurologist in Portugal during the recruitment period. In each center, consecutive recruitment in the 
outpatient clinic will be stimulated to avoid selection bias.  
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5.1 INCLUSION CRITERIA 
 
Study subjects must fulfill the following criteria: 
1. Patients alive and with the diagnosis of MS in any day of May 2014 (Positive McDonald 2010 
criteria for Multiple Sclerosis, including “no better explanation”). 
2. Informed consent. 
 
5.2 EXCLUSION CRITERIA 
 
Subjects will be excluded if at least one of the following criteria is met: 
 
1. No positive McDonald 2010 criteria. This includes the exclusion of patients with an alternative 
clinical diagnosis more plausible than Multiple Sclerosis even if other aspects of McDonald 
2010 are satisfied. 
2. No informed consent.   
6 STUDY PROCEDURES/INFORMATION TO BE COLLECTED 
 
 
 All neurologists in Portugal who follow patients with MS will be contacted (or can contact the PORT-
MS study Coordinating Committee directly) to integrate the study as investigators and introduce data 
from their patients (hospital-based study). If a certain neurologist is willing to participate, he/she will 
contact his institution’s (Neurology department) director and other superiors, or the Coordinating 
Committee will accomplish that role, to ask permission to carry the study there. The study will then be 
submitted to the ethics committee of each institution (as well as to the hospital administration) and 
wait for approval. As a principal investigator (PI) must be identified for each institution, in those 
places where various neurologists will be investigators, the PI will try to stimulate recruitment by 
reminding their colleagues or by helping collecting/gathering data from the patient, if the neurologist 
that recruited and follows the patient consents.  
 
After identifying their patients and ask for informed consent, data will be collected from the patient’s 
file and he/she could answer to some questions to complete informations that are missing, both at a 
single time point. The participant’s contribution will then be finished and he won’t be subjected to any 
other evaluation. 
 
Data will be introduced in a paper CRF. The CRF will be mailed to an address to the Coordinating 
Committee. 








Informed consent should be kept in the patients’ hospital file and an entry in that file should state that 
the patient has been included in the PORT-MS study and eventually describe his/her number in that 
database (CRF code). This will permit future doctors of that patient to be sure his data has been 
introduced in the database. 
 
Data can actually be collected/gathered by any other investigator of that same institution if that’s the 
wish of the recruiting investigator and if it’s easier in terms of institutional organization. For each 
patient there are 3 investigators involved  (corresponding to different roles in the process) and listed 
(the same person can assume the 3 roles, though): the investigator that gathered the data and 
introduces it the CRF; the investigator that is actually the doctor that follows and treats that patient 
and recruited it; and a general responsible for the consultation of MS in that institution or the service 
director. 
 
Please refer to the CRF later in this protocol to analyze data that will be collected. 
 
Recruitment is expected to occur between June 2014 and August 2014 for the first step, until June 




7.1 PRIMARY ENDPOINT 
 
Main variables include: date of birth, place of birth, sex, ethnic origin, race, date of first symptoms, 
place of residency at first symptoms, date of diagnosis, place of residency at diagnosis, initial type of 
MS, date of start of secondary progressive MS, current treatment and date of start of that treatment, 
EDSS, employment status, previous participation in clinical trials. Please see CRF for details. 
 
7.2  SECONDARY ENDPOINTS 
 
Not applicable. 
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8 STATISTICAL ANALYSIS 
 
Variables will be described through descriptive statistics, namely absolute (n) and relative frequencies 
(%) for qualitative variables and mean, median, standard deviation (SD), minimum and maximum for 
quantitative variables. 
All patients with data at least in name initials, date of birth, sex and date of diagnosis will be 
considered, even if missing variables exist. Missing values will not be substituted. 




New safety findings that can potentially affect the risk/benefit profile of a medicinal product identified 
during the conduct of epidemiological studies will be reported promptly to the Health Authorities, 
according to local pharmacovigilance regulations. 
 




The study will be conducted according to the ethics principles originated from the Declaration of 
Helsinki and the applicable privacy laws. 
A copy of the protocol, proposed informed consent form and other written subject information will be 
submitted to the local Ethics Committee for written approval. A copy of the written approval of the 
protocol and informed consent form must be received by the Investigator before recruitment of 
subjects and data collection. 
The investigator will submit and, where necessary, obtain approval from the local Ethics Committee 
for all subsequent protocol amendments and changes to the informed consent document.  
 
 
10.2 RISK/BENEFIT ASSESSMENT 
 
 
This is an observational study. The sole specific procedure the patient will be subjected to is to 
answer the questions of the CRF questionnaire.  








10.3 INFORMED CONSENT 
 
Before any protocol specific procedures are performed, the investigator is responsible for 
obtaining written informed consent from the subject (or authorized representative) and after 
an adequate and clear explanation of the aims, methods, anticipated benefits, and potential 
hazards of the study.  
The informed consent process should be documented in the subject’s medical charts, and 
the informed consent form should be signed and personally dated by the subject (or 
authorized representative, if applicable) and by the person who conducted the informed 
consent discussion (not necessarily an investigator). The original signed informed consent 
form should be retained in accordance with institutional policy, and a copy of the signed 
consent form should be provided to the subject or authorized representative. 
 
11 DATA HANDLING 
11.1 CONFIDENTIALITY 
 
The investigator is responsible for ensuring that the subject’s confidentiality is maintained. 
Questionnaires, database and other documents generated in this study will be identified by a unique 
subject identification number only. This number will be assigned sequentially, based on subject’s 
recruitment schedule. Each study site will also be assigned a number.  
The study will be notified to the Comissão Nacional para Protecção de Dados, under the scope of “Lei 
de Protecção de Dados de Carácter Pessoal Dec. 67/98 de 26 de Outubro” and Deliberação da CNPD 
nº 227/2007. 
 
11.2 DATA COLLECTION  
 
All study data will be obtained from review of medical charts and subject’s interview. All the 
information will be collected into a structured questionnaire (case report form), specifically 
designed for this research.  
The investigator will be responsible for ensuring that all findings and data are accurately and 
reliably recorded in the case report form.  
All corrections in the data originally recorded in the case report form or in any other study 
document should be performed in a way that the original record is still legible, and should be 
dated and signed by the investigator. 
 




Protocol, version3, March 2014   Page 15 of 29 
 
 
11.3 STUDY ARCHIVE 
The investigator will keep and adequate archive of all study documentation with access 
restricted to study team. The study archive will be kept at each site for at least 15 years 
from the study’s close out.  
11.4 PUBLICATION POLICY  
 
All documents and results generated from this clinical study are exclusive property of the PORT-MS 
Study Group, represented by the Coordinating and Scientific Committees. Any related publications 
must be previously approved in written by the Coordinating Investigator.  
All investigators who contribute to the collection of data by implementing the study in their center, by 
recruiting their patients or by actually collecting data, will be mentioned in the CRF, are authors of 
publications and constitute part of the “PORT-MS study group”. 
To accomplish the objectives of the EMIN course of MS and the first step of this study mentioned in 
the Rationale section of this protocol, one or two publications with initial procedures and preliminary 
results can be submitted by the Implementing Committee as sole authors (expectedly by the end of 
2014).  
Afterwards, publications will be coordinated by the coordinating investigator and the coordinating 
committee with the help and review of the scientific committee. Other experts, coming from the 
PORT-MS study group or external, may be integrated as necessary. Work groups can be set for a 
particular matter or paper.  
As articles and other types of works or presentations have a limited number of authors visible, a 
ranking of authors apply as follows: the group of investigators that directly contributes to that 
particular work or paper (by analyzing data, writing the article, etc.) – presumably elements from the 
Implementing Committee and the Scientific Committee plus experts integrated - followed by the list of 
investigators in the registry ordered by the number of patients included (or “used”) in that particular 
study, until the maximum number of authors permitted. The designation “PORT-MS study group” 
must always be referred in any work that includes any part of data coming from this registry and, 
whenever possible (for instance in online appendixes of articles), a complete list of contributors should 
be added.  
It’s not an objective of this study no analyze the  number of patients per hospital or per doctor and 
that data will not be published or known outside the Coordinating Committee of the PORT-MS study 
group.
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13  APPENDICES 
Appendix A  
Paper CRF. Data collected by the CRF will be in Portuguese, as follows: 
 
Este caderno de recolha de dados deve ser preenchido pelo médico retirando dados do processo do 
doente e questionando o doente directamente (após o devido consentimento informado).  
Gere um código para este CRF do seguinte modo iniciais do doente como põe em baixo na primeira 
questão seguido dos algarismos da data de nascimento. Exemplo: JMF02051968. Deste modo pode 
colocar no processo do doente que o mesmo foi integrado no MS-PORT. 
Código gerado para este CRF:_________________________ 
 
Iniciais dos primeiros 3 nomes do doente  
Instrução: Conta o nome como está no BI/cartão do cidadão do doente e não como está no processo 
hospitalar. Exemplo: Tânia Nunes Gonçalves será TNG. Os nomes hifenizados separam-se. Anulam-
se apenas as partículas “de”/ “da”/”do”/”e”. Maria de Fátima Antunes será apenas MFA; Ribeiro-da-
Cunha fica RC. Outras partículas estrangeiras ficam e quando juntas ao nome fica apenas a primeira 
letra: O'Neil será apenas O; D'Orey fica D; McGregor será M. Caso o doente só tivesse 2 nomes 
introduza “A” como inicial do 3º nome. 
 
Comentário: O único propósito desta colheita é detectar, junto com a data de nascimento, doentes 
repetidos, quer porque foram introduzidos em duplicado no mesmo centro, quer porque são seguidos 
em 2 centros diferentes 
 




Sexo (à nascença) 
Masculino / Feminino 
 
Este doente nasceu em Portugal (território actual, continental e insular)? 
Sim/Não 
 
Se nasceu em Portugal, Freguesia e Concelho em que nasceu.  
Freguesia____________________________ 
Concelho_____________________________ 
Comentário: Pretende-se detectar eventuais regiões com número de doentes assimetricamente 
elevado por comparação com a população de base. Vai-se depois tentar saber o código postal 
(aproximado) dessa freguesia para fazer um mapa de distribuição da doença. O propósito do 
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concelho é diferenciar entre freguesias com nomes iguais. 
 
Nascimento fora de Portugal e períodos em que viveu fora de Portugal.  
 
País________ ; permaneceu desde idade (*)_______ até idade (*)_______ ; permaneceu desde data 
(ano)_______ até data (ano)_______ 
País________ ; permaneceu desde idade (*)_______ até idade (*)_______ ; permaneceu desde data 
(ano)_______ até data (ano)_______ 
País________ ; permaneceu desde idade (*)_______ até idade (*)_______ ; permaneceu desde data 
(ano)_______ até data (ano)_______ 
 
 
Instrução: Consideraremos o nascimento fora de Portugal sempre assinalável mesmo que tenha 
regressado para o país ou tenha transitado para outra região com menos de 1 ano de vida. Assim, se 
nasceu fora de Portugal, coloque o país onde nasceu, na idade de início escreva “nascimento” e 
depois até quantos dias/meses/anos de idade lá esteve. Clarifique com “dias” ou “meses” ou “anos”. 
Para situações que não envolvam o nascimento considere apenas períodos de residência fora do 
país superiores a um ano. Escolha esclarecer entre uma data e outra ou entre uma idade e outra (ou 





Peso_____________Kg     
Altura_______________cm 
Origem étnica / “raça”, escolha: 
Branca / Negra / Cigana / Árabe (norte de África e Médio Oriente) /  Sul asiática (Índia, 
Paquistão e países da região) /  Sudeste asiática (Tailândia, Indonésia e países da região) / 
Extremo Oriente (China, Japão países da região) / Mista / Outra, especifique 
________________ 
 
Data dos primeiros sintomas de EM 
__/____ 
Instrução: Mm/aaaa. Detalhe o máximo que souber mas pode pôr mês-ano ou só ano. Esta 
informação reveste-se de alguma valorização subjectiva quando se trata de colheita anamnéstica 
restrospectiva. Com base no seu julgamento clínico terá que valorizar o que pensa terem sido os 
primeiros sintomas. 
 
Estes primeiros sintomas, escolha uma: 
 São apenas valorizados e referidos retrospectivamente pelo doente não tendo sido 
especificamente observado por um médico por causa deles (porque, por exemplo, o doente não 
valorizou na altura ou não teve oportunidade de recorrer a médico) 
 Terão sido observados por um médico (e portanto terá havido registos contemporâneos em algum 
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lugar tenha ou não acesso a eles) mas não terão sido correctamente interpretados ou investigados e 
acabaram por não desencadear o diagnóstico 
 Terão sido observados por um médico (e portanto terá havido registos contemporâneos em algum 
lugar tenha ou não acesso a eles) e foram em termos gerais adequadamente interpretados tendo 
contribuido para o diagnóstico final (nessa altura ou mais tarde) 
 
Freguesia e Concelho de residência na altura dos primeiros sintomas 
Freguesia____________________________ 
Concelho_____________________________ 
Comentário: Pretende-se detectar eventuais regiões com número de doentes assimetricamente 
elevado por comparação com a população de base. Vai-se depois tentar saber o código postal 
(aproximado) dessa freguesia para fazer um mapa de distribuição da doença. O propósito do 
concelho é diferenciar entre freguesias com nomes iguais. 
 
Data do diagnóstico 
__/____ 
Instrução: Mm/aaaa. Os critérios de diagnóstico têm variado ao longo das últimas décadas, sendo 
hoje possível diagnosticar a doença mais cedo no seu percurso do que anteriormente. Considere os 
critérios de diagnóstico referentes à época em que o diagnóstico foi efectuado não sendo necessário 
mudar essa data baseado nos conhecimentos actuais. Se o doente tiver sido diagnosticado fora do 
seu hospital ou por outro clínico, poderá ter que considerar a data em que pela primeira vez um 
neurologista achou que o diagnóstico era EM e que estavam cumpridos os critérios da altura. Detalhe 
o máximo que souber mas pode pôr mês-ano ou só ano.  
 
Freguesia e Concelho de residência na altura do diagnóstico 
Freguesia____________________________ 
Concelho_____________________________ 
Comentário: Pretende-se detectar eventuais regiões com número de doentes assimetricamente 
elevado por comparação com a população de base. Vai-se depois tentar saber o código postal 
(aproximado) dessa freguesia para fazer um mapa de distribuição da doença. O propósito do 
concelho é diferenciar entre freguesias com nomes iguais. 
 
Tipo inicial de EM 
SR (surto-remissão) / SR (surto-remissão) mas na altura do diagnóstico já estava em SP 
(secundária progressiva) / PP (primária progressiva) / PP com surtos / fase muito inicial ainda 
tenho duvidas no perfil de evolução do doente. 
 
Instrução: escolha aquilo que retrospectivamente acha que é o tipo de EM inicial do doente.  
 
Para os doentes que terão iniciado sob forma de surto-remissão: este doente já atingiu no seu 
entender a fase secundária progressiva? 
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Não / Sim, desde  __/____  
 
Instrução: Detalhe o máximo que souber mas pode pôr mês-ano ou só ano.  
 
Em Maio de 2014 este doente estava sob terapêutica modificadora da doença? 
 
Sim:  
QUAL: Interferão B-1a sub-cutâneo 22ug 3 x por semana / Interferão B-1a sub-
cutâneo 44ug 3 x por semana / Interferão B-1a intramuscular 1 x por semana / 
Interferão B-1b sub-cutâneo em dias alternados / Acetato de Glatirâmero / 
Natalizumab / Fingolimod / Mitoxantrona / Dimetilfumarato / 
Teriflunomida / Alemtuzumab / Rituximab / Ocrelizumab / Azatioprina / 





Instrução: Mm/aaaa. Detalhe o máximo que souber mas pode pôr mês-ano ou só 
ano. Refira-se apenas à terapêutica que estava a fazer em Janeiro de 2014 (a 
última que fez nesse mês, se por acaso começou a primeira ou mudou de 
terapêutica nesse mês) 
 
HAVIA EFECTUADO OUTRAS TERAPÊUTICAS MODIFICADORAS DA DOENÇA 
PREVIAMENTE? 




Não estava sob terapêutica sobretudo por decisão do doente (independentemente 
da razão)? 
Sim / Não 
 
HAVIA EFECTUADO TERAPÊUTICAS MODIFICADORAS DA DOENÇA 
PREVIAMENTE? 




EDSS em Maio de 2014  










Instrução: caso o doente estivesse se encontrasse num decurso de um surto em Maio 2014 ponha a 
EDSS após a recuperação total desse surto caso tenha acesso a ela, ou a EDSS prévia a esse surto 
caso não esteja disponível a EDSS após o surto. 
 
Valor de EDSS exacto, se disponível: _______ 
 
Se não dispuser de EDSS exacto, tente colher informação para escolher uma das seguintes 
categorias: 
 0-4.0 (totalmente ambulatório, capaz de caminhar 500 m sem ajuda ou descanso)  
 4.5 (capaz de caminhar sem ajuda ou descanso 300m)  
 5.0 (capaz de caminhar sem ajuda ou descanso 200m) 
 5.5 (capaz de caminhar sem ajuda ou descanso 100m) 
 6.0 (necessita de ajuda intermitente ou constante (nesta caso apenas unilateral) (bengala, 
canadiana, tala) para caminhar 100m com ou sem descanso) 
 6.5 (necessita de ajuda constante bilateral (bengalas, canadianas, talas) para caminhar 100m com 
ou sem descanso) 
 7.0-7.5 (essencialmente confinado a cadeira de rodas) 
 8.0-9.5 (desde “maior parte do dia na cama” até totalmente acamado) 
 
 
EDSS sub-ítem Funções Mentais em Maio de 2014 
 0 Normal 
 1 Alteração do humor 
 2 Dimiuição mental ligeira 
 3 Diminuição mental moderada 
 4 Diminuição mental marcada (síndroma cerebral orgânica crónica moderada) 
 5 Demência ou síndroma cerebral orgânica crónica grave 
 V Desconhecido 
 
Em Maio 2014 o doente encontrava-se no decurso de um surto? 
Não  / Sim 
 
Considera que existem interferências significativas na captura da EDSS deste doente por outras 
doenças ou condições que tornem este resultado pouco fidedigno para estadiar a incapacidade 
relacionada com a EM? 
Sim / Não 








A incapacidade global permanente (física e mental, incluindo neurológica não apenas relacionada 
com EDSS e não neurológica – exemplos: insuficiência cardíaca severa, problemas 
ortopédicos marcados) deste doente: 
 Relaciona-se essencialmente com a Esclerose Múltipla 
 Existem outras patologias com peso semelhante ao da Esclerose Múltipla ou pelo menos bastante 
considerável 
 É essencialmente relacionada com outras patologias 
Este doente tentou alguma vez obter um grau de incapacidade junto da segurança social?  
Sim / Não 
Se tentou, conseguiu?  
Não  / Sim.  
Indique o grau ou, pelo menos, se é >60% 
Grau ________________%, >60% 
 
Anos de escolaridade _________ 
Instrução: soma dos anos de estudo (tempo primordialmente dedicado aos estudos) em instituição 
que fornece graus académicos reconhecidos, reflectindo o nível de escolaridade referido abaixo (anos 
repetidos não contam) 
 
Nível de escolaridade 
 
Analfabeto / Sem escolaridade mas sabe ler e escrever / Frequentou a escola primária / 
Completou 4a classe / Frequentou ensino preparatório ou secundário (ou antigas escola 
comercial ou industrial) / Completou 9º ano (antigo 5º ano dos liceu ou escola comercial ou 
industrial) / Completou curso profissionalizante após o 9º ano / Completou 12º ano (antigo 7º ano 
dos liceus) / Completou bacharelato  ou frequentou ensino superior / Completou licenciatura / 
Completou mestrado / Completou doutoramento 
 
Situação Laboral  
Instrução:  
Tome por referencia a última semana antes deste questionário. 
Emprego é trabalho pago ou originando ganho, na semana em que estamos a considerar, podendo 
ser muito tansitório ou com contrato precário (implicito, explícito, oral, escito), independentemente do 
número de horas. Aquilo que comumente se designa por “doméstico” não constitui um emprego, 
assim como não o é a produção agrícola em baixa quantidade para consumo próprio - se essa 
pessoa não procura um emprego ou não deja um, classifica-se como população não activa, se o 
desejar e procurar classifica-se com activa desempregada. Trabalhos exclusivamente transitórios por 
determinação do indíviduo, como é exemplo trabalho em férias escolares, numa pessoa que fora isso 
não procura um emprego, não consideraremos emprego. Não nos interessa aqui a natureza 
específica do trabalho ou aspectos legais, se auferir ganhos com o seu trabalho está empregado. A 
única excepção é se receber subsídio de desemprego, nesse caso consideraremos desempregado. 




Protocol, version3, March 2014   Page 23 of 29 
 
 
POPULAÇÃO ACTIVA: tem um emprego ou, não tendo emprego, deseja um (está “disponível” para 
um emprego) e procura-o activamente. Classifica-se assim independentemente de, simultaneamente, 
ser reformado, estudante etc.  
POPULAÇÃO NÃO ACTIVA: não tem emprego e ou não deseja um ou não o procura (ou ambos).  
 
 Este doente inclui-se na população ACTIVA – está a executar algum tipo de trabalho remunerado 
ou que lhe origina ganhos ou, não tendo emprego, deseja um (está “disponível”) e procura-o 
activamente.  
Tem emprego / teve na última semana. (Pessoas apenas temporariamente fora 
do emprego por qualquer razão mas mantendo algum vínculo com ele são 
incluidas aqui.)  
 
Tem (ou teve na última semana) apenas um emprego /  Vários 
 
Detalhe o estatuto do emprego (caso tenha vários, detalhe o mais relevante deles): 
 a) Empregado (o habitual “por conta de outrém”, pago a unidade de tempo, de 
produto produzido, podendo incluir comissões, etc.) 
 Emprego prolongado mas com vínculo fraco (exemplo: 
empregada doméstica com contrato oral) 
                          Emprego sem termo com contrato regular (com contribuições 
para segurança social etc) 
 Termo fixo, curto-termo, casual, on-demand, sazonal  e similares 
independentemente do tipo de contrato 
 b) Empregador (Trabalhador por conta própria e tem sob contrato pelo menos 
uma pessoa como empregado, independentemente do tipo de contrato.) 
 c) Trabalhador por conta própria. (A remuneração depende do lucro que se 
obterá com o produto e pode variar no tempo. Comissões e similares não cabem 
nesta definição, geralmente trata-se de trabalho por conta de outrém.)  
 d) Membros de cooperativas   
 e) Contribui para uma empresa familiar não sendo propriamente um “sócio” 
dessa empresa e geralmente não pago directamente   
 f) Não classificável nestas categorias ou informação insuficiente 
____________________________________ 
 
Quantas horas trabalha em média por semana (ou na última semana, se trabalhos 
inconstantes) – inclui horas extraordinárias mesmo em casa e pagas apenas 
parcialmente se directamente relacionado com o emprego em questão 
_______________h 
 
Considera o doente que a Esclerose Múltipla actualmente interfere na capacidade 
de desempenho ou o número de horas de trabalho de forma “SIGNIFICATIVA”? 
(não só na última semana, aqui referimo-nos em termos gerais) 
Não / Sim 








Se sim, é capaz de dar uma idéia do número de horas que teve que 
eventualemente reduzir no seu volume de trabalho semanal, em média, por 
comparação com um período em que não tinha a doença ou que a doença não 
interferia com a sua capacidade laboral? _______________________h 
 
Segundo o doente, a interferência da doença deve-se sobretudo a (pode escolher 
várias): 
 Alterações físicas e/ou mentais da doença ou dela decorrentes (como por 
exemplo depressão) 




Está desempregado (não tem um trabalho assalariado ou por conta própria + 
está disponível para trabalhar (deseja-o, seja por que motivo for) + procura 
activamente emprego).  
 
Se possível, escolha a melhor opção:  
 a) Desemprego Voluntário (Não econtra o emprego com as características que 
quer (função ou salário) e portanto não se emprega. Pode estar a receber 
benefícios do estado ou não. Seria possivel arranjar outro emprego noutra área 
mas não está interessado.) 
 b) Desemprego Involuntário (restantes situações) 
______________________________________________ 
Já trabalhou no passado (no sentido de “ter um emprego” segundo a definição 
atrás mencionada)? 
Sim /  Não 
 
Considera o doente que a Esclerose Múltipla interefe significativamente com a sua 
oportunidade de encontrar emprego? 
Sim, é a principal interferência 
Sim, mas é apenas uma interferência entre várias outras causas 
Não 
 
Este doente inclui-se na população NÃO ACTIVA – não tem actualmente emprego e não deseja um 
ou não o procura. (Não pode escolher simultaneamente activa e não activa, escolha apenas uma 
destas opções.)  
 
Dentro desta opção, escolha a situação mais relevante neste caso. Se existem 
várias situações comente as secundárias em baixo, assim como outras dúvidas: 








Sem idade mínima para trabalhar (em Portugal pode-se trabalhar 
excepcionalmente e com condicionantes abaixo dos 16 anos se já tiver concluido a 
escolaridade obrigatória ou estiver a fazer formação para a concluir, pode-se 
trabalhar a partir dos 16 anos se tiver concluido a escolaridade obrigatória ou 
estiver a fazer formação para a concluir, é-se livre de trabalhar a partir dos 18) 
Estudante (frequência regular de instituição educacional pública ou privada para 
instrução sistemática em qualuer nível educacional) 
“Doméstico” (actividades no seu próprio domicilio para “consumo” do mesmo) 
Pessoa com lucros de capital (investimentos, rendas,etc) 
Reformado (tem pensão de actividade económica prévia ou tem reforma da 
segurança social “por idade”) 
Pessoa com pensões de invalidez/doença 
Recebe ajudas de terceiros (ajudas de privados, de instituições públicas ou 
privadas, etc) 




Gostaria de ter um emprego mas sente-se desencorajado e desistiu de procurar 
(hidden unenmployment)? 
Sim / Não 
 
Se sim, pensa do doente que a Esclerose múltipla é a principal razão desta 
situação? 





Por causa da Esclerose Múltipla, o doente considera que precisa de um cuidador de forma 
“SIGNIFICATIVA” e do qual não precisaria sem a doença? 
Não / Sim 
 
Este doente alguma vez participou num ensaio clinico (estudo intervencional - fase III ou anterior) 
com um medicamento modificador da doença? 
Sim / Não 
 
Este doente tem algum familiar directo com EM? 
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Instrução: Considerar apenas casos mais consistentes em que esses familares são ou terão seguidos 
por neurologista 
Sim: irmão/irmã ; filho/filha ; pai/mãe ; avô/avó paterno ou materno ; tio/tia em primeiro 




Para doentes do sexo feminino 
 
Número de gestações após o diagnóstico de EM _______   
Número de partos (nados vivos) após o diagnóstico de EM _________ 
 
Médico que introduz os dados 
Nome clínico___________________ / OM______________ 
 
Médico que segue o doente 
Nome clínico___________________ / OM______________ 
 
Responsável pela consulta de EM / Director de serviço  
Nome clínico___________________ / OM______________ 
 
Nota: a colheita do nome dos médicos envolvidos no recrutamento deste doente é feita apenas por 
questões de autoria de publicações relacionadas com este estudo. 
  
DATA DE PREENCHIMENTO DO CRF ___ / ___/_______ 
 








Appendix B –  
Informed consent in Portuguese 
 
 
INFORMAÇÃO AO DOENTE 




O seu neurologista está a convidá-lo para participar neste estudo porque tem o diagnóstico de 
Esclerose Múltipla.  
Trata-se de um estudo observacional, durante o qual o seu médico o seguirá e tratará de acordo com 
a prática clínica habitual, procedendo apenas à recolha de dados sobre si. Este estudo pretende fazer 
um retrato demográfico e clínico básico dos doentes com Esclerose Múltipla em Portugal ao longo de 
2014 e até 2016. Pretende-se integrar o maior número possível de doentes com Esclerose Múltipla 
em Portugal. Está prevista apenas uma colheita sumária de dados de cada doente numa única altura 
e depois todos os dados serão analizados em conjunto. Esses dados incluem a idade de início dos 
sintomas, a idade com que foi diagnosticado, a sua freguesia de nascimento, a freguesia em que 
reside, o tipo de doença que tem e o tratamento que está a fazer, assim como dados básicos acerca 
da sua escolaridade, emprego, cuidador e família. Alguns dados poderão já constar do seu processo 
pelo que com a sua permissão o neurologista poderá retirá-los de forma anónima. Poderá ter que 
responder a algumas questões para completar os dados. Os seus dados serão colhidos de forma 
anónima, apenas com as suas iniciais e a sua data de nascimento. Os dados serão misturados com 
os dados de centenas ou milhares de outros doentes. 
 
A realização do estudo foi aprovada pela Comissão de Ética para Saúde (CES) do seu hospital. As 
comissões de ética são também responsáveis pela proteção dos direitos das pessoas que participam 
em investigação clínica. 
 
 
É obrigatório participar no estudo? 
A sua participação neste estudo é completamente voluntária. Cabe-lhe a si decidir se quer ou não 
participar. Se decidir participar, é livre de desistir em qualquer altura. Caso desista, não incorrerá em 
qualquer penalização e tal não afetará o seu tratamento nem os cuidados médicos a que tem direito.  
 
Quais são os possíveis riscos e benefícios? 
A sua participação neste estudo não envolve riscos, uma vez que não será alterada a prática médica 
habitual e apenas se procederá à recolha de dados. Não vemos nenhuma desvantagem específica 
para sí ao integrar este estudo fora o facto de poder ter que responder a algumas questões para 
completar dados que não constam do seu processo clínico. Também não há vantagens directas 
específicas fora o facto de contribuir para que a doença seja mais conhecida, estudada e falada em 
Portugal. Ao integrar os dados de todos os doentes estaremos mais perto da realidade. Se muitos 
doentes ficarem de fora não conheceremos a realidade tal como ela é a a doença terá uma imagem 
falsa na comunidade. 
 
 
Não terá qualquer encargo financeiro adicional por participar neste estudo.  
 
Não está previsto nenhum pagamento ao seu médico para integrar os seus dados nesta base de 
dados embora este estudo procure financiamento de várias entidades para pagar múltiplos tipos de 
custos e alguns médicos ou outros profissionais que vão trabalhar os dados centralmente possam ser 
pagos. 
 
A participação é confidencial? 
Sim, foi pedida autorização à Comissão Nacional de Proteção de Dados (CNPD) para a recolha e uso 
dos seus dados de saúde, garantindo a sua confidencialidade, de acordo com a Legislação 
Portuguesa sobre Proteção de Dados, nomeadamente a Lei nº 67/98 de 26 de Outubro e a 
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Deliberação 227/2007, de 28 de Maio. Assim, todos os dados recolhidos serão utilizados de forma 
completamente anónima, apenas identificados por um código numérico, sem fazer referência aos 
seus dados pessoais, permanecendo a sua identidade confidencial. Se der o seu consentimento para 
participar neste estudo, os seus registos médicos poderão ser analisados pelas autoridades 
regulamentares, Comissões de Ética para a Saúde e pelos monitores do responsável pelo tratamento 
dos dados, para garantir que os dados e procedimentos do estudo estão a ser efetuados de acordo 
com o protocolo e requisitos legais. Esta validação será realizada, sempre que possível, na presença 
dos investigadores do estudo, que são responsáveis pela garantia da confidencialidade dos seus 
dados. Os dados anonimizados não serão transmitidos para países fora da União Europeia (UE). 
Ao assinar este consentimento, está a dar a sua permissão para que tal possa ocorrer. Esta 
informação permanecerá estritamente confidencial e nenhuma informação que o identifique será 
tornada pública.  
Os resultados deste estudo podem vir a ser publicados em revistas médicas e apresentados em 
reuniões científicas. No entanto, não será identificado pelo nome em nenhuma destas publicações. 
 











































Aceito participar neste projeto e autorizo a recolha dos meus dados para um caderno de recolha 
de dados específico do estudo, de acordo com os pressupostos descritos atrás. 
 
_______________________________ 
Nome do Doente (em letra de imprensa) 
 
___________________________________  ______________ 
Assinatura do Doente      Data  
Se o doente estiver mentalmente incapacitado para dar o seu consentimento:  
Aceito participar neste projeto e autorizo a recolha dos dados para um caderno de recolha de 
dados específico do estudo, de acordo com os pressupostos descritos atrás. 
 
Nome do Representante Legal (em letra de imprensa) 
 
___________________________________  ______________ 
Assinatura do Representante Legal    Data  


































O doente foi por mim informado sobre a natureza e objetivo deste estudo. 
 
_____________________________________________________ 
Nome do Médico (em letra de imprensa) 
 
___________________________________  ______________ 
Assinatura do Médico      Data 
Se o doente não estiver em condições para dar o seu consentimento por escrito, apenas oral 
(doente iletrado ou fisicamente incapacitado):  
 Aceito participar neste projeto e autorizo a recolha dos dados para um caderno de recolha de 
dados específico do estudo, de acordo com os pressupostos descritos atrás. 
 
__________________ 
Nome da 1ª testemunha (em letra de imprensa) 
 
__________________________________  ______________ 




Nome da 2ª testemunha (em letra de imprensa) 
 
__________________________________  ______________ 
Assinatura da 2ª testemunha     Data 
Se o doente for menor de idade: 
Sou eu que decido participar, ou não, neste estudo. Seja qual for a minha decisão, ninguém ficará 
zangado comigo. Se eu quiser sair do estudo, basta dizer aos meus pais ou ao meu médico.  
 Concordo em participar no estudo. 
 
________________________              ___________________ 
Assinatura do doente      Data 
 
A natureza deste estudo de investigação clínica e o papel do doente foram descritos a 
______________________________________________(nome do doente) de forma adequada ao 
seu nível de desenvolvimento. Ele/ela compreende e aceita participar no estudo. 
 
 
______________________________________         ______________________ 
Assinatura dos pais/ tutor legal     Data 
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Constitution of the PORT-MS Study Group 
 
All the investigators that participated in this study until the present phase are listed in Table 
39. Professor Armando Sena, who contributed to the review of this Master’s Dissertation, is 
the only contributor not represented in the Table. Like the case of Professor Armando Sena, 
other investigators will be added as needed in the following phases of the study. 
The roles of the investigators are explained in the Protocol section. 
 
Center Investigators 





Centro Hospitalar de São João 







Maria José Sá 
Centro Hospitalar do Porto 




Ana Martins da Silva 
Centro Hospitalar Universitário de Coimbra 
 
José Tomás 









Centro Hospitalar de Lisboa Norte 
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Centro Hospitalar de Lisboa Central 






Table 39. Constitution of the PORT-MS study group. 
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Public presentations of results of the PORT-MS study 
 
1. Alegria P, Samões R, Ferreira J, Sequeira J, Grilo M, Tomás J, Varanda S, Cerqueira J, 
Sousa L, Pedrosa R, da Silva AM, Sá J, Vale J, Sá MJ; PORT-MS Study-Group. A cross-
sectional national study on the demography, disease characteristics and socioeconomic 
status of the Portuguese patients with Multiple Sclerosis - the PORT-MS study. Oral 
presentation. Reunião de Outono do GEEM (Grupo de Estudos de Esclerose Múltipla da 
Sociedade Portuguesa de Neurologia), session dedicated to the presentation of the final 
works developed during the EMIN 2nd edition course (a one year duration course on 
MS for residents in Neurology sponsored by the GEEM and Biogen Idec); 2014 December  
13th; Lisbon, Portugal. Portuguese/English. Winner on the EMIN 2nd edition course. 
2. Miguel Grilo, João Sequeira, José Tomás, Sara Varanda, João Ferreira, Raquel Samões, 
Carlos Capela, Ernestina Santos, Sónia Batista, Pedro Abreu, João Cerqueira, Lívia Sousa, 
Rui Pedrosa, Ana Martins da Silva, João Sá, José Vale, Maria José Sá, Paulo Alegria; PORT-
MS Study-Group. Demography, clinical characteristics and socioeconomic status of the 
Portuguese patients with Multiple Sclerosis in 2014 – results of the national cross-
sectional PORT-MS study. Poster presentation. Third International Porto Congress of 
Multiple Sclerosis; 2015 Feb; Porto, Portugal.  
3. Sara Varanda, Raquel Samões, João Ferreira, José Tomás, Miguel Grilo, João Sequeira, 
Joana Morgado, Carlos Andrade, Jorge Reis, Joana Guimarães, Lívia Sousa, João 
Cerqueira, José Vale, Maria José Sá, João Sá, Ana Martins da Silva, Rui Pedrosa, Paulo 
Alegria; PORT-MS Study-Group. Trends in the treatment of Multiple Sclerosis in Portugal 
in 2014 – results of the national cross-sectional PORT-MS study. Third International 
Porto Congress of Multiple Sclerosis; 2015 Feb; Porto, Portugal. Winner of the best oral 
communication. 
4. J. Tomás, J. Dias Ferreira, J. Sequeira, M. Grilo, R. Samoes, S. Varanda, J. Morgado, J. 
Guimaraes, C. Nunes, J. J. F. C. A. Cerqueira, J. M. Vale Santos, M. J. Sá, A. A. D. M. Silva, 
L. M. A. F. D. Sousa, R. M. G. Pedrosa, J. de Sa, P. Alegria; PORT-MS Study-Group. 
Demography, clinical characteristics and socioeconomic status of the Portuguese 
patients with Multiple Sclerosis in 2014 – results of the national cross-sectional PORT-
MS study. European Academy of Neurology 2015. Accepted. 
5. R. Samoes, S. Varanda, M. Grilo, J. Sequeira, J. Tomás, J. Ferreira, M. D. C. R. R. M. 
Macário, C. M. C. Capela, E. Santos, L. M. A. F. D. Sousa, R. M. G. Pedrosa, J. de Sa, M. J. 
Paulo Alegria  Master’s Dissertation  2015  Page 97 
Faculdade de Ciências Médicas, Universidade Nova de Lisboa  College of Professional Studies, Northeastern University 
 
Sá, J. M. Vale Santos, J. J. F. C. A. Cerqueira, A. A. D. M. Silva, P. Alegria; PORT-MS Study-
Group. Economic activity and employment of the Portuguese patients with Multiple 
Sclerosis in 2014 - results of the national cross-sectional PORT-MS study. European 
Academy of Neurology 2015. Accepted. 
6. João Sequeira, José Tomás, Raquel Samões, João Ferreira, Sara Varanda, Miguel Grilo, 
Sónia Batista, Rita Simões, Paula Esperança, José Vale, Maria José Sá, João de Sá, Ana 
Martins da Silva, Rui Pedrosa, Lívia Sousa, João Cerqueira, Paulo Alegria; PORT-MS 
Study-Group. Tratamento da Esclerose Múltipla em Portugal em 2014 – resultados do 
estudo transversal multicêntrico PORT-MS. Forum 2015 da Sociedade Portuguesa de 
Neurologia. Submitted.  
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Presentations of parts of these work won the following prizes: 
- Best work (first prize) of the EMIN 2nd edition, a one year duration course on MS for 
residents in Neurology sponsored by the GEEM (Grupo de Estudos de Esclerose 
Múltipla of the Sociedade Portuguesa de Neurologia) and Biogen Idec. Attributed 
during the meeting  Reunião de Outono do GEEM 2014; 2014 December  13th; Lisbon, 
Portugal. 
- Best oral communication of the Third International Porto Congress of Multiple Sclerosis; 
2015 Feb; Porto, Portugal. 
